All conditions

Colorectal Cancer

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

3997
Trials on record
614
Recruiting now
14
Australian sites
61
Phase 3 trials
6
PBS medicines
How these figures are counted
  • Trials on record is every trial tagged to this condition at any stage, except those withdrawn before starting or terminated early. Most are completed rather than ongoing, so this is a measure of research history, not of current activity. It is also smaller than the sitewide "trials tracked" figure, which does include withdrawn and terminated trials.
  • Recruiting now counts only trials whose registry status is "Recruiting". Trials listed as not yet recruiting or enrolling by invitation are excluded, so this understates how many may open to new participants soon.
  • Australian sites counts trials counted under "Recruiting now" that list at least one Australian site. A site being listed does not mean it is currently enrolling, and Australian trials registered only on ANZCTR are not counted yet, so this understates local availability.
  • Phase 3 trials counts trials counted under "Recruiting now" that are at Phase 3.

Find recruiting trials for Colorectal Cancer →

Get alerts when Colorectal Cancer trials change ↗

Voxsanity currently covers 103 conditions. We are expanding coverage regularly.

Understanding Colorectal Cancer

Colorectal cancer is a cancer that starts in the colon (large bowel) or the rectum, which are parts of the digestive system. It usually begins as small growths called polyps on the inner lining of the bowel. Over time, some of these polyps can become cancerous. The cancer can sometimes spread to nearby lymph nodes or other parts of the body if it is not caught early. Receiving this diagnosis can feel overwhelming, and it is completely normal to have many questions.

Colorectal cancer is one of the most common cancers in Australia. It affects both men and women, and the risk increases with age, particularly for people over 50. Australia has a national bowel cancer screening program because early detection makes a significant difference in outcomes. Family history, lifestyle factors, and certain bowel conditions can also increase a person's risk. You are far from alone in facing this diagnosis — thousands of Australians are diagnosed each year, and there is a well-established network of medical specialists and support services available.

Treatment depends on a number of factors, including the size and location of the cancer, whether it has spread, and a person's overall health. Common treatment approaches include surgery to remove the affected part of the bowel, chemotherapy, and radiation therapy, which are sometimes used in combination. Some people may also be offered targeted therapy or immunotherapy, depending on the specific characteristics of their cancer. A team of specialists — often including surgeons, oncologists, and nurses — will work together to discuss the options that are most appropriate for each individual's situation.

This overview is an AI generated summary written from public medical sources and checked on a sample basis. It is general information, not medical advice or a diagnosis. Always speak with your doctor about your situation. How we use AI

Can you access treatment for Colorectal Cancer in Australia right now? Here's what's publicly known.

Information on this site does not constitute medical advice. Data is sourced from publicly available government registries. Always consult your doctor before making any health decisions. Trial status should be verified directly with the trial site.

Updated regularly from public government registries

PBS-subsidised medicines for Colorectal Cancer

6 medicines listed on the PBS for Colorectal Cancer. Filter by authority type, or open the full table below.

What the authority types mean Unrestricted: no clinical criteria; a doctor can prescribe it on the PBS for any appropriate use. Restricted benefit: subsidised only for the specific conditions or uses set out by the PBS. Streamlined authority: restricted, but the doctor does not need prior approval; they record a streamlined authority code confirming you meet the criteria. Authority required: restricted, and the doctor must get prior approval from Services Australia (by phone or online) before it is subsidised. Source: Pharmaceutical Benefits Scheme (pbs.gov.au).
Full PBS medicines table 6 listed

These medicines are listed on the Pharmaceutical Benefits Scheme (PBS) for the specific indications shown. A listing does not mean a medicine is right for you; your doctor decides what is appropriate. Prices shown are the PBS-determined dispensed price. Most patients pay only the standard co-payment, up to AU$25.00 per script (general) or AU$7.70 (concession or Safety Net) in 2026, with the Australian Government subsidising the rest.

Medicine Brand(s) Listed for
Cetuximab Erbitux colorectal cancer Metastatic AU$268.53 Streamlined authority
Encorafenib Braftovi colorectal cancer Metastatic AU$1675.18 Streamlined authority
Fruquintinib Fruzaqla colorectal cancer Metastatic AU$1319 Streamlined authority
Panitumumab Vectibix colorectal cancer Metastatic AU$450.42 Streamlined authority
Trifluridine + tipiracil Lonsurf 15/6.14, Lonsurf 20/8.19 colorectal cancer Metastatic AU$707.14 Streamlined authority
Pembrolizumab Keytruda deficient mismatch repair (dMMR) colorectal cancer Unresectable or metastatic AU$3632.56 Authority required

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.

Research pipeline

Where trials for Colorectal Cancer currently sit in the development pipeline. The funnel shape shows how few drugs reach later phases in general; the counts are this condition's actual trial numbers.

Phase success rates are industry-wide historical averages, not predictions for specific trials. Learn how trials work →

Most active research sponsors

Organisations with the most recruiting trials for Colorectal Cancer.

View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile

Where trials are running

Clinical trial sites for Colorectal Cancer by country. Australia is highlighted.

Showing the top 10 of 64 countries with trial sites.

Clinical trials for Colorectal Cancer

Showing 617 of 617 trials

The plain English eligibility text on each trial below is an AI generated summary of the official criteria, checked on a sample basis. How we use AI

🇦🇺 NCT00457691 · Pfizer Phase 3 · 34 countries Completed
Completed Phase 3 Est. completion 1 March 2010
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE Bosnia and Herzegovina🇧🇷 BR🇧🇬 BG🇨🇦 CA +26 more

Who might be able to join this trial: - You have been diagnosed with colorectal cancer (cancer of the colon or rectum) that has spread to other parts of the body, confirmed by a laboratory test of a tissue or cell sample - You have not yet received any treatment for your cancer that has spread, but your doctor has reco...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02060188 · Bristol-Myers Squibb Phase 2 · 8 countries Completed
Completed Phase 2 Est. completion 22 October 2024
🇦🇺 AU🇧🇪 BE🇨🇦 CA🇫🇷 FR🇮🇪 IE🇮🇹 IT🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** - You are generally active and able to carry out daily activities with little to no limitation (confirm with trial site for exact fitness level required) - You have been diagnosed with colorectal cancer that has come back or spread to other parts of the body, confirmed by a tis...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04456699 · Merck Sharp & Dohme LLC Phase 3 · 18 countries Completed
Completed Phase 3 Est. completion 27 March 2023
🇦🇺 AU🇧🇪 BE🇨🇦 CA🇨🇱 CL🇨🇴 CO🇫🇷 FR🇩🇪 DE🇭🇺 HU +10 more

**Who might be able to join this trial:** - You have been diagnosed with colorectal cancer (a type of bowel cancer) that has spread to other parts of the body or cannot be removed by surgery, confirmed by a tissue biopsy. - Your cancer did not get worse (it stayed stable or improved) after receiving at least 6 rounds...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT00843375 · University of Michigan Rogel Cancer Center Not Applicable · 3 countries Recruiting
Recruiting Not Applicable Est. completion 1 March 2028
🇦🇺 AU🇨🇦 CA🇺🇸 US

Who might be able to join this trial: - You must be willing to sign a consent form to take part in the study - You must be able to have up to 60 ml of blood drawn (about 4 tablespoons) without it being a health risk for you - You must be 18 years old or older - You must be willing to collect 1 to 2 stool samples and co...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT04008407 · Western Sydney Local Health District Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2027
🇦🇺 AU

Who might be able to join this trial: - People who have been referred for surgical removal of large, flat or spreading growths in the colon. - People who are able to give their informed consent to take part in the trial. Who may not be able to join: - People who have previously had a removal procedure attempted or com...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT04929223 · Hoffmann-La Roche Phase 1 · 11 countries Recruiting
Recruiting Phase 1 Est. completion 31 August 2030
🇦🇺 AU🇨🇦 CA🇩🇰 DK🇩🇪 DE🇮🇹 IT🇵🇱 PL🇰🇷 KR🇪🇸 ES +3 more

**Who might be able to join this trial:** - People who are 18 years of age or older at the time of signing the consent form - People who have signed the specific consent form for their group (cohort) in the trial - People whose tumour has been tested for certain genetic markers/mutations using an approved, certified l...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05041478 · Western Sydney Local Health District Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2028
🇦🇺 AU

**Who might be able to join this trial:** - Adults over 18 years of age who are scheduled to have a colonoscopy and have given written consent to take part in the trial - People who have at least one flat or slightly raised abnormal growth (lesion) in the colon or rectum that appears non-cancerous based on its surface...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT05253651 · Seagen, a wholly owned subsidiary of Pfizer Phase 3 · 25 countries Recruiting
Recruiting Phase 3 Est. completion 31 December 2027
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE🇧🇷 BR🇨🇦 CA🇨🇱 CL🇨🇳 CN +17 more

**Who might be able to join this trial:** - People who have been diagnosed with colorectal cancer (cancer of the colon or rectum) that has spread to other parts of the body or cannot be surgically removed, confirmed by a laboratory test on a tissue or cell sample. - People who are able to provide a stored tumour tissu...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05759728 · Carina Biotech Limited Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇦🇺 AU

**Who might be able to join this trial:** - People who have signed a written consent form agreeing to take part. - Adults aged 18 or older, of any gender. - People who are relatively well and able to carry out daily activities, as measured by a standard medical scale (ECOG score of 0 or 1 — confirm with trial site). -...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05855200 · GlaxoSmithKline Phase 3 · 28 countries Recruiting
Recruiting Phase 3 Est. completion 19 March 2029
🇦🇷 AR🇦🇺 AU🇧🇪 BE🇧🇷 BR🇨🇦 CA🇨🇳 CN🇨🇿 CZ🇪🇪 EE +20 more

**Who might be able to join this trial:** - People who have been diagnosed with colon cancer (a specific type called adenocarcinoma) that has not yet been treated - People whose colon cancer has been confirmed by a pathology test (laboratory analysis of tissue) - People whose cancer is considered removable by surgery,...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06050707 · University Health Network, Toronto Phase 2 · 3 countries Recruiting
Recruiting Phase 2 Est. completion 1 September 2028
🇦🇺 AU🇨🇦 CA🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with squamous cell carcinoma (a type of cancer) of the anal canal or anal margin, confirmed by a tissue test. This includes certain related cancer cell types (such as basaloid or cloacogenic). - People whose cancer is at a stage that has not spread...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06252649 · Amgen Phase 3 · 35 countries Recruiting
Recruiting Phase 3 Est. completion 25 September 2028
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE🇧🇷 BR🇧🇬 BG🇨🇦 CA🇨🇱 CL +27 more

Who might be able to join this trial: - People who have been diagnosed with colorectal cancer that has spread to other parts of the body (metastatic), confirmed by a lab test to have a specific gene change called KRAS p.G12C mutation. - People whose KRAS p.G12C mutation has also been confirmed by the trial's central la...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06976710 · Surgical Outcomes Research Centre (SOuRCe) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 July 2028
🇦🇺 AU

Who might be able to join this trial: - Adults aged 18 or older who are scheduled to have planned (non-emergency) major surgery for colon or rectal cancer, with the goal of curing the cancer - People who have an appointment with a colorectal cancer surgeon at least one week before their scheduled surgery date Who may...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT06997497 · Merck Sharp & Dohme LLC Phase 3 · 28 countries Recruiting
Recruiting Phase 3 Est. completion 28 March 2029
🇦🇷 AR🇦🇺 AU🇧🇷 BR🇨🇦 CA🇨🇱 CL🇨🇳 CN🇨🇴 CO🇫🇮 FI +20 more

Who might be able to join this trial: - People who have been diagnosed with colorectal cancer (a type of bowel cancer) that has been confirmed by a lab test and has either spread to other parts of the body or cannot be removed by surgery (Stage III unresectable or Stage IV) - For Part 2 of the trial only: People who ha...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07221357 · Bristol-Myers Squibb Phase 3 · 26 countries Recruiting
Recruiting Phase 3 Est. completion 2 February 2030
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE🇧🇷 BR🇨🇦 CA🇨🇱 CL🇨🇳 CN +18 more

**Who might be able to join this trial:** - People who have been diagnosed with colorectal cancer (a type of bowel cancer) that has come back or spread to other parts of the body, confirmed by a tissue sample, and have not yet received treatment for this advanced stage of the disease. - People whose cancer cannot be r...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07235293 · Kahr Bio Australia Pty Ltd Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 30 September 2026
🇦🇺 AU🇺🇸 US

Who might be able to join this trial: - People aged 18 or older who are expected to live for more than 3 months - People who have been diagnosed with a specific type of colorectal cancer (confirmed by tissue testing) that cannot be removed by surgery, has certain molecular features (known as MSS and/or pMMR), and has c...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07244705 · Anbogen Therapeutics, Inc. Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 1 April 2028
🇦🇺 AU🇹🇼 TW

**Who might be able to join this trial:** - People who are 18 years of age or older at the time of signing the consent form - People who have been diagnosed with advanced or returning colorectal cancer (CRC) that has been confirmed by laboratory tissue testing, has at least one measurable area of disease, and has been...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02070146 · Dutch Colorectal Cancer Group Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2050
🇳🇱 NL

Who might be able to join this trial: - Adults aged 18 years or older. - People who have been diagnosed with colorectal cancer, small bowel cancer, or anal cancer confirmed by a tissue test, or where imaging results strongly suggest one of these cancers. - People who have given their consent to have their health inform...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02107105 · M.D. Anderson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2030
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with rectal cancer (a specific type called adenocarcinoma, at any stage from I to IV), confirmed through a laboratory test of tissue, where surgery aimed at curing the cancer is planned or has already taken place - People who are able to read and wr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02292641 · Imperial College London Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇳🇴 NO🇬🇧 GB

**Who might be able to join this trial:** - People who have had colorectal cancer (a cancer of the large bowel or rectum) confirmed by a biopsy taken during normal medical care - People who have been diagnosed with colorectal cancer that has come back in the pelvic area (the lower part of the abdomen) - People who have...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02328677 · University of Utah Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 October 2030
🇩🇪 DE🇺🇸 US

Who might be able to join this trial: - Adults between 18 and 89 years old (note: for people enrolled after September 1, 2021, the age range is generally 18 to 69, though older age groups may be included under certain parts of the study — confirm with trial site) - Both men and women are eligible - People who have been...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02669992 · Karolinska University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇸🇪 SE

Who might be able to join this trial: - People who have had a temporary loop ileostomy (a surgical opening in the abdomen to divert the bowel) created during rectal cancer surgery - People whose doctors have determined that closing the ileostomy is medically appropriate and safe based on standard clinical practice Who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02704520 · Imperial College London Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇬🇧 GB

Who might be able to join this trial: - People who have rectal cancer that has been assessed by MRI scan and meets at least one of these features: the tumour has grown significantly into or beyond the rectal wall, cancer has spread into nearby blood or lymph vessels as seen on MRI, cancer has spread to nearby lymph nod...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02869503 · Institut Paoli-Calmettes Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2030
🇫🇷 FR

"Who might be able to join this trial: - People who have been diagnosed with colorectal cancer (cancer of the colon or rectum) Who may not be able to join: - No specific exclusion criteria have been listed for this trial (confirm with trial site) Important: Always verify eligibility with the trial site directly befor...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02919644 · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. I... Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇮🇹 IT

**Who might be able to join this trial:** - People who have been diagnosed with stage IV colorectal cancer through tissue testing, and who have had surgery with the aim of completely removing the cancer. - The tissue sample removed during surgery must have been collected and sent to a specific laboratory (IRST IRCCS)...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02966483 · Sun Yat-sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with rectal cancer that has been confirmed by a tissue biopsy (adenocarcinoma type) - People whose tumour is located in the lower part of the rectum (below a certain point in the abdomen) - People whose rectal cancer is considered treatable with...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02997293 · University of Arkansas Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2028
🇺🇸 US

Who might be able to join this trial: - Men and women aged 18 or older who had major bowel or colon surgery at the University of Arkansas for Medical Sciences during either January 1, 2014 to December 31, 2014, or June 1, 2015 to November 30, 2016. - People who, at the time of their surgery, were rated as relatively he...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03303495 · Sun Yat-sen University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2026
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with colorectal cancer (specifically adenocarcinoma) that cannot be removed by surgery, not including cancer of the appendix or anal canal - People aged 18 or older at the time of giving consent to participate - People whose general physical conditi...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03303833 · Wageningen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2030
🇳🇱 NL

Who might be able to join this trial: - You have been tested and found to carry a known gene change (mutation) that causes Lynch syndrome, specifically in one of these genes: MLH1, MSH2, MSH6, PMS2, or EPCAM. - You are between 18 and 80 years old at the time of joining the trial. Who may not be able to join: - You als...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03349762 · Xi Shan Wang Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People between 18 and 75 years old (male or female) - People who have had surgery to remove colorectal cancer for the first time, within the last two months, where lab results after surgery confirmed the cancer was at stage IIB, IIC, or III - People with a general health and...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03465982 · Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandri... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 5 June 2025
🇮🇹 IT

Who might be able to join this trial: - People who are over 18 years old - People whose rectal cancer has been confirmed by CT scan and MRI as a specific stage (a tumour that has grown through the bowel wall and may or may not have spread to nearby lymph nodes, but has not spread to distant parts of the body) - People...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03466424 · Fujian Medical University Union Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2025
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with rectal cancer (confirmed by biopsy) that is at a certain stage (T3-4 and/or has spread to nearby lymph nodes), has not been treated before, can be removed by surgery, and is located within 12 cm of the anal opening - Men or women who are not pr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03516708 · Washington University School of Medicine Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 July 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been newly diagnosed with locally advanced rectal cancer (confirmed by tissue testing), at a stage that their doctor has classified as Stage 2 or 3, or Stage 1 where surgery to preserve the sphincter muscle is not possible, and whose treatment plan includes a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03587480 · Sixth Affiliated Hospital, Sun Yat-sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 24 May 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with rectal cancer (a type of gland-based cancer located in the lower part of the bowel, below a certain internal boundary called the peritoneal reflection), confirmed through a tissue test - People whose cancer is classified as Stage III - Peo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03594630 · M.D. Anderson Cancer Center Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 31 October 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with rectal adenocarcinoma (a specific type of rectal cancer), confirmed through laboratory testing of tissue. - People whose cancer is considered suitable for surgery with the goal of removing it completely (curative resection). - People whose...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT03659448 · Surgimab Phase 3 · 4 countries Recruiting
Recruiting Phase 3 Est. completion 1 November 2024
🇩🇪 DE🇮🇹 IT🇳🇱 NL🇺🇸 US

**Who might be able to join this trial:** - People who are scheduled for surgery aimed at curing colorectal cancer, including advanced colon cancer (called cT4), rectal cancer that has grown into or through the bowel wall (cT3 or cT4), colorectal cancer that has come back, or colorectal cancer that has spread to the li...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03667170 · 3D Medicines (Sichuan) Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with locally advanced or metastatic colorectal cancer, or another type of solid tumour cancer, confirmed through a tissue sample test. - People whose tumour has tested positive for a specific genetic feature known as MMR deficiency or MSI-H (a m...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03671252 · Sun Yat-sen University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 25 September 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 75 years old - People who have been diagnosed with rectal cancer (specifically a type called adenocarcinoma), confirmed by tissue testing - People whose tumour is located close to the anal opening (5 cm or less away) and where the cancer has grown...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03692429 · Celyad Oncology SA Phase 1 · 2 countries Recruiting
Recruiting Phase 1 Est. completion 28 November 2021
🇧🇪 BE🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with colorectal cancer (cancer of the colon or rectum) that has spread to other parts of the body and cannot be removed by surgery, confirmed through a tissue biopsy. - People whose cancer has come back or continued to grow after receiving at l...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03715933 · Inhibrx Biosciences, Inc Phase 1 · 6 countries Recruiting
Recruiting Phase 1 Est. completion 1 December 2028
🇫🇷 FR🇮🇹 IT🇳🇱 NL🇪🇸 ES🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - People aged 12 to under 85 years with Ewing sarcoma, or aged 18 to under 85 years with other cancer types included in the trial - People with Ewing sarcoma that has spread, cannot be removed by surgery, has come back, or has stopped responding to treatment, and who have had...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03731130 · Ludwig-Maximilians - University of Munich Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2021
🇩🇪 DE

Who might be able to join this trial: - People who have been diagnosed with rectal cancer that has been confirmed by a tissue sample (biopsy), and the cancer has not spread to other parts of the body - People whose cancer care team has recommended radiation therapy or a combination of radiation and chemotherapy before...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03748485 · Sixth Affiliated Hospital, Sun Yat-sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who, before surgery, were assessed as having stage III colorectal cancer (cancer that has spread to nearby lymph nodes but not to distant organs) - People whose colorectal cancer was confirmed as a specific type called adenocarcinoma through a biopsy taken during a col...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03779009 · University Hospital, Ghent Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇧🇪 BE

**Who might be able to join this trial:** - People who have been diagnosed with adenocarcinoma (a specific type of cancer) of the colon - People whose cancer has not spread to nearby lymph nodes or other parts of the body (classified as Stage II) - People whose cancer can be surgically removed - People who are mentall...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03841799 · Centre Leon Berard Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇫🇷 FR

**Who might be able to join this trial:** - People aged 18 or older at the time of signing the consent form - People in Cohort A: those with a benign or cancerous colorectal (bowel) growth (ranging from early to moderate stage) who are suitable for surgery, and who have not previously received any cancer-fighting medi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03919461 · Assaf-Harofeh Medical Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 28 February 2027
🇮🇱 IL

**Who might be able to join this trial:** - People aged 20 to 80 years old - People who are scheduled for surgery to remove colon or rectal cancer, with the goal of curing the cancer - People who have a single colon or rectal cancer tumour, confirmed by a full colonoscopy and biopsy - People who have no signs of cancer...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03925662 · Sherief Abd-Elsalam Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2028
🇪🇬 EG

Who might be able to join this trial: - People who have been diagnosed with stage 4 colorectal cancer (bowel cancer that has spread to other parts of the body). Who may not be able to join: - People who have agranulocytosis (a condition where the body has very low levels of a type of white blood cell that fights infec...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03926338 · Sun Yat-sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 April 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing and able to sign a written consent form - People who have been confirmed, through a tissue or cell sample, to have cancer of the colon or rectum (adenocarcinoma) - People whose tumor has been tested and found to have a specific genetic feature known as...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03957902 · Instituto de Investigación Sanitaria Aragón Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2025
🇪🇸 ES

**Who might be able to join this trial:** - You are aged 18 or older but under 80 years old - You have recently been diagnosed with colon or rectal cancer within the last 48 hours, confirmed by a camera examination of the bowel and a laboratory analysis of tissue samples - Your blood clotting and general blood test res...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03961776 · Institut Paoli-Calmettes Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 May 2022
🇫🇷 FR🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older. - People who have been diagnosed with rectal cancer (a specific type called rectal adenocarcinoma), confirmed by tissue testing, for which a combination of chemotherapy and radiation therapy before surgery has been recommended. - People whose general...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03998202 · Wake Forest University Health Sciences Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

Who might be able to join this trial: - People who have been newly diagnosed with colorectal cancer that has spread to other parts of the body (metastatic), or whose colorectal cancer has come back in a spreading form at least 3 months after finishing treatment for an earlier, non-spreading form of the disease. - Peopl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04006951 · Institut du Cancer de Montpellier - Val d'Aurelle Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇫🇷 FR

Who might be able to join this trial: - People who are being treated at the Montpellier Cancer Institute, for any type of treatment (such as medication-based cancer treatment, radiation therapy, or surgery) - People who are over 18 years of age - People who have signed a consent form agreeing to take part in the study...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04050345 · Royal Marsden NHS Foundation Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2029
🇬🇧 GB

**Who might be able to join this trial:** **Part B (before surgery):** - People who have been newly diagnosed with colorectal cancer (confirmed by tissue testing) and are scheduled for surgery aimed at curing the cancer, with no signs of the cancer having spread to other parts of the body - People whose tissue testing...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04094454 · Juergen Debus Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2026
🇩🇪 DE

**Who might be able to join this trial:** - You are female - You have been diagnosed with squamous anal cancer, confirmed through a tissue sample (biopsy) - Your doctor has recommended radiation therapy as your main treatment or after surgery - You are reasonably active and able to care for yourself (your doctor will a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04103567 · Institut du Cancer de Montpellier - Val d'Aurelle Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 January 2026
🇫🇷 FR

**Who might be able to join this trial:** - People who have been diagnosed with cancer in the lower or middle part of the rectum (confirmed by laboratory testing of tissue), at stage II or stage III - People who are planned to receive pre-surgery treatment, such as a combination of radiation and chemotherapy, chemother...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04120935 · IFOM ETS - The AIRC Institute of Molecular Oncology Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇮🇹 IT🇪🇸 ES

Who might be able to join this trial: - People who are 18 years of age or older - People who have previously been diagnosed with colorectal cancer, or where there is a strong suspicion of colorectal cancer based on clinical and imaging results - People who have stored tissue samples from their colorectal cancer diagnos...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04130971 · Sahlgrenska University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇸🇪 SE

"Who might be able to join this trial: - People who have been diagnosed with colorectal cancer (cancer of the colon or rectum) Who may not be able to join: - People who do not have a diagnosis of colorectal cancer Important: Always verify eligibility with the trial site directly before applying."

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04184973 · Colospan Ltd. Not Applicable · 5 countries Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇩🇪 DE🇮🇱 IL🇮🇹 IT🇨🇭 CH🇺🇸 US

Who might be able to join this trial: - People who are willing to attend and complete all follow-up appointments required by the study. - People who are between 22 and 65 years old at the screening visit, or between 66 and 70 years old with no more than one heart, metabolic, or lung condition for which medication has b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04185272 · Institut Paoli-Calmettes Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2027
🇫🇷 FR

**Who might be able to join this trial:** - People who are older than 18 years old - People who have signed a consent form agreeing to take part - People diagnosed with colon cancer that has not spread (non-metastatic) and can be operated on straight away, or people whose colon cancer has spread to the liver at the sam...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04185779 · South Tyneside and Sunderland NHS Foundation Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 August 2024
🇬🇧 GB

**Who might be able to join this trial:** **Group A:** - People aged 30 or older who are able to agree to take part in the study - People attending a colonoscopy through the Bowel Cancer Screening Programme (for example, following a positive stool test, a bowel scope conversion, or as part of ongoing monitoring) - Peo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04190589 · Vejle Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇩🇰 DK

**Who might be able to join this trial:** - You have a suspected or confirmed colon cancer that has been seen on a colonoscopy and CT scan, located in a specific part of the large bowel (the upper right side or the right two-thirds of the middle section of the colon) - You are 18 years of age or older, able to make you...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04215731 · Yanhong Deng Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 September 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing and able to sign a written consent form agreeing to take part - People who are older than 18 and younger than 70 years of age - People who have been diagnosed with a specific type of rectal cancer (adenocarcinoma) confirmed by tissue testing, located w...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04258137 · Institut Bergonié Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇫🇷 FR

**Who might be able to join this trial:** - People aged 18 or older - People diagnosed with colorectal cancer or non-small cell lung cancer - People whose cancer is locally advanced, cannot be removed by surgery, and/or has spread to other parts of the body - People whose general health and ability to carry out daily...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04389086 · Catharina Ziekenhuis Eindhoven Phase 3 · 5 countries Recruiting
Recruiting Phase 3 Est. completion 1 March 2024
🇧🇪 BE🇳🇱 NL🇳🇴 NO🇵🇹 PT🇸🇪 SE

Who might be able to join this trial: - People who are 18 years of age or older - People who have rectal cancer that has come back in the same area after previous surgery to remove rectal or lower colon cancer, confirmed either by tissue biopsy or by scans and clinical assessment agreed upon by a specialist team - Peop...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04462042 · Umeå University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2026
🇸🇪 SE

**Who might be able to join this trial:** - You must be at least 18 years old - You have been diagnosed with a specific type of anal cancer (squamous cell carcinoma of the anal canal), confirmed by a tissue sample, that has not been treated before - Your cancer must be at a certain stage — not too small, and not yet sp...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04486131 · Amsterdam UMC, location VUmc Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇳🇱 NL

**Who might be able to join this trial:** - You have rectal cancer and at least one swollen lymph node in the side of your pelvis that is either 7mm or larger, or between 5–7mm but shows one or more signs of concern (such as a round shape, uneven edges, mixed appearance, or loss of normal structure) on a scan. **Who m...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04489238 · Memorial Sloan Kettering Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 22 July 2026
🇺🇸 US

**Who might be able to join this trial:** **For the YOGI group (database and questionnaire):** - People who have been diagnosed with a gastrointestinal cancer, confirmed by a tissue or cell sample test - People who were between 18 and 49 years old at the time of agreeing to take part - For the stool sample collection...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04495088 · Ralf Hofheinz Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 August 2030
🇩🇪 DE

**Who might be able to join this trial:** - People (male or female) who have been diagnosed with rectal cancer (a specific type called adenocarcinoma), confirmed by a tissue sample, located in the rectum within a certain distance from the anal opening - People whose cancer staging has been assessed using a high-resolu...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04511039 · Roswell Park Cancer Institute Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 September 2028
🇺🇸 US

**Who might be able to join this trial:** - People with a confirmed diagnosis of colorectal cancer (CRC) or a type of stomach/digestive tract cancer called gastric adenocarcinoma, where the cancer has spread or cannot be removed by surgery (Cohort A); or people with confirmed colorectal cancer with specific genetic fe...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04525989 · Alexander Valdman Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2028
🇸🇪 SE

Who might be able to join this trial: - People who have been newly diagnosed with rectal cancer (confirmed by biopsy), where the lowest part of the tumour is within 16 cm of the opening of the back passage, measured using a special viewing instrument. - People whose cancer is locally advanced and shows at least one hig...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04547166 · Shanghai Henlius Biotech Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 24 September 2025
🇨🇳 CN🇯🇵 JP

**Who might be able to join this trial:** - People who have been diagnosed with colorectal cancer (a type of bowel cancer) that has spread to other parts of the body or come back, and cannot be removed by surgery — confirmed by lab testing of tissue samples - People whose doctors estimate they are likely to live for a...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04592003 · University Hospital, Limoges Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2026
🇫🇷 FR

**Who might be able to join this trial:** - People who are being referred for a colorectal ESD (a procedure used to remove abnormal tissue from the colon or rectum) **Who may not be able to join:** - People who have formally stated they do not wish to take part, after reading the information notice provided about the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04636008 · West China Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2024
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with rectal cancer (adenocarcinoma) confirmed by a laboratory tissue test - People whose cancer has a specific genetic feature called dMMR or MSI-H (a marker found through tumour testing), whether or not they have Lynch syndrome - People who ha...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04643041 · Sixth Affiliated Hospital, Sun Yat-sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with rectal cancer (a specific type called adenocarcinoma), confirmed by a tissue sample test - Your tumour has a specific genetic feature called "dMMR" or "MSI-H," identified through laboratory testing of your tumour tissue - Scans show your tumour i...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04643366 · Virginia Commonwealth University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 January 2030
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with rectal adenocarcinoma (a specific type of rectal cancer) confirmed by tissue biopsy within the past 90 days, where at least part of the tumour is in the lower section of the rectum - People whose cancer has been staged using the AJCC 8th e...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04673955 · Pierre Fabre Pharma GmbH Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇦🇹 AT🇩🇪 DE

**Who might be able to join this trial:** - People aged 18 or older who are able to make their own legal decisions - People who have colorectal cancer that has spread to other parts of the body (metastatic), with a specific genetic change called the BRAF V600E mutation, and who have already received at least one previo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04677413 · University of Texas Southwestern Medical Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 June 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older, of any gender, race, or ethnic background - People who are willing and able to sign a written consent form agreeing to take part - People who have been diagnosed with a specific type of rectal cancer called rectal adenocarcinoma - Peop...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04678011 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 November 2026
🇳🇱 NL🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with Familial Adenomatous Polyposis (FAP), either through a genetic test showing a specific gene mutation, or because they were found to have more than 100 growths in the large bowel along with a family history of FAP - People who have already had s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04689347 · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 April 2026
🇮🇹 IT

**Who might be able to join this trial:** - People who have been diagnosed with colorectal cancer (cancer of the colon and/or rectum) that has spread to other parts of the body, confirmed by laboratory testing of tissue samples. - People whose tumor has a specific genetic feature called MGMT promoter methylation (conf...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04701853 · Göteborg University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇸🇪 SE

Who might be able to join this trial: - People who are scheduled to have a permanent colostomy (a surgical opening created in the abdomen for waste to leave the body, using part of the large intestine called the sigmoid colon) Who may not be able to join: - People who do not speak Swedish - People who have a condition...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04703101 · Jonsson Comprehensive Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 October 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with rectal cancer (a specific type called adenocarcinoma) confirmed by a tissue sample. - People whose cancer has been classified by MRI scan as either Stage II (a certain tumour size with no spread to nearby lymph nodes) or Stage III (varying...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04739072 · M.D. Anderson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older - People who have been confirmed through a tissue or cell sample to have colorectal adenocarcinoma (a type of bowel cancer) - People with colorectal adenocarcinoma at any stage where treatment aimed at curing the disease is being considered, including...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04743102 · Beijing Chao Yang Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2023
🇨🇳 CN

**Who might be able to join this trial:** - Adults between 18 and 80 years old (male or female) - People whose tissue sample (biopsy) from a colonoscopy has confirmed a type of bowel cancer called colorectal adenocarcinoma - People whose tumour is located close to the lower end of the bowel — within a specific distanc...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04749108 · Institut du Cancer de Montpellier - Val d'Aurelle Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 August 2026
🇫🇷 FR

**Who might be able to join this trial:** - You have given written consent to take part - You are currently receiving a chemotherapy regimen called Folfirinox - You are 18 years of age or older - Your general health and activity level meets a certain minimum standard as rated by your doctor (confirm with trial site) -...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04751448 · Baylor Research Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with colon cancer - People who are older than 18 and no more than 79 years of age - People who are able to understand and agree to participate by signing a consent form - People whose treatment plan includes a chemotherapy combination called FOLFOX...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04754672 · Radboud University Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2026
🇳🇱 NL

**Who might be able to join this trial:** - People who have metastatic colorectal cancer (cancer of the colon or rectum that has spread to other parts of the body) and whose doctors have recommended palliative chemotherapy (chemotherapy aimed at managing the disease rather than curing it) - People who are scheduled to...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04767568 · Centre Hospitalier Universitaire de Besancon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2027
🇫🇷 FR

**Who might be able to join this trial:** - People who are over 18 years old - People in Cohort A: those who have had a positive stool blood test during bowel cancer screening (a test that detects blood in the stool) or who have visible bleeding, and colorectal cancer is suspected — OR people in Cohort B: those who hav...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04779554 · Prakash Pandalai Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 February 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with one of the following: low-grade appendiceal mucinous neoplasm, pseudomyxoma peritonei, appendiceal cancer that has spread to the lining of the abdomen, or colorectal cancer that has spread to the lining of the abdomen - People whose genera...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04792892 · Sahlgrenska University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2025
🇸🇪 SE

Who might be able to join this trial: - Adults over 18 years of age - People who have been diagnosed with anal squamous carcinoma (a specific type of anal cancer) within the last 2 months Who may not be able to join: - People who are unable or unwilling to provide informed consent (formal written agreement to particip...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04808323 · Medical College of Wisconsin Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 14 April 2027
🇺🇸 US

Who might be able to join this trial: - People aged 18 or older - People who have been diagnosed with rectal cancer (specifically a type called adenocarcinoma), confirmed by a tissue or cell sample - People whose cancer has been assessed as stage I, II, or III (meaning it has not clearly spread to other parts of the bo...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04815525 · Chinese University of Hong Kong Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
Hong Kong

Who might be able to join this trial: - People who have had a colonoscopy performed at a Hospital Authority (HA) hospital during the study period. Who may not be able to join: - People who have a documented personal history of colorectal cancer that was diagnosed before the study period began. Important: Always verif...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04816292 · Technical University of Munich Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2026
🇩🇪 DE

Who might be able to join this trial: - You have a medical reason to have a colonoscopy - At least one polyp (a small growth) between 10 and 15 mm was found in your colon during a colonoscopy - You have read and signed a consent form agreeing to take part Who may not be able to join: - You have been assessed by an ana...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04824053 · Instituto de Investigación Sanitaria Aragón Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2027
🇪🇸 ES

**Who might be able to join this trial:** - You have been diagnosed with high-risk polyps through a colorectal cancer screening programme, a family history-based prevention programme, or you are already being monitored after polyps were previously found — and your situation includes at least one of the following: 10 o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04861558 · Uppsala University Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 1 December 2025
🇮🇳 IN🇸🇪 SE

**Who might be able to join this trial:** - People who are able and willing to provide written consent before any study procedures begin - People whose general health and ability to carry out daily activities falls within an acceptable range, as measured by standard medical scoring tools (confirm with trial site) - Peo...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04871399 · University of Turin, Italy Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇮🇹 IT

Who might be able to join this trial: - People who have been assessed by an anaesthesia specialist and rated as having a general health status of Grade I, II, or III (meaning from healthy to having some serious but controlled medical conditions). - People diagnosed with cancer in the right side of the colon (from the c...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04894370 · Centre Hospitalier Universitaire de Besancon Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2025
🇫🇷 FR

**Who might be able to join this trial:** - People aged 18 or older, of any gender - People who are generally well enough to carry out daily activities with little or no limitation (as assessed by a standard medical scale called ECOG-WHO, with a score of 0 or 1) - People who have been diagnosed with squamous cell canc...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04920032 · University of California, Irvine Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 21 January 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with colon cancer (or certain types of rectal cancer that was removed without needing radiation), confirmed by a tissue or cell sample analysis - People with Stage II, Stage III, or Stage IV colorectal cancer who have had surgery with the goal...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04927897 · Maastricht Radiation Oncology Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
🇳🇱 NL

Who might be able to join this trial: - People who are 18 years of age or older and are able to understand and agree to participate in the trial. - People who have been diagnosed with rectal cancer (a type of cancer called adenocarcinoma) that has been confirmed by examination or scans, has not spread to nearby lymph n...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04938986 · Hospital St. Joseph, Marseille, France Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2028
🇫🇷 FR

**Who might be able to join this trial:** - Adults aged between 18 and 80 years old (inclusive) - People who have been diagnosed with colon adenocarcinoma (a specific type of colon cancer), confirmed through laboratory testing of tissue - People who have had surgery to fully remove stage I, II, or III colorectal cancer...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04949646 · Larissa University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 19 September 2027
🇬🇷 GR

**Who might be able to join this trial:** - You have been diagnosed with rectal cancer that has been confirmed through a laboratory test of tissue samples - You are having or have had surgery to remove the rectum using a specific technique called Total Mesorectal Excision (TME) (confirm with trial site) - You are under...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04959604 · Universitätsklinikum Hamburg-Eppendorf Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇩🇪 DE

"Who might be able to join this trial: - People who have been diagnosed with cancer of the colon (specifically the ascending, transverse, descending, or sigmoid sections) confirmed through a tissue sample test. Who may not be able to join: - People who do not wish to take part in the trial. - People whose colon cancer...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04967183 · Fundacin Biomedica Galicia Sur Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2025
🇪🇸 ES

**Who might be able to join this trial:** - People who are between 50 and 65 years old. - People who have had at least one advanced polyp (a type of growth in the colon of a certain size or with specific cellular features) or at least three smaller polyps found and fully removed during a routine bowel cancer screening...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04980287 · Jichao Qin Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 19 July 2023
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 75 years - People whose overall health has been assessed by an anaesthesiologist and falls within a low-to-moderate risk range (ASA score I to III) - People who have had a biopsy that confirmed a diagnosis of colorectal cancer (cancer of the colon o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04991948 · Celyad Oncology SA Phase 1 · 2 countries Recruiting
Recruiting Phase 1 Est. completion 21 August 2023
🇧🇪 BE🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with colorectal cancer (cancer of the colon or rectum) that has spread to other parts of the body and cannot be removed by surgery, confirmed by laboratory testing of tissue. - People whose tumor has been tested and does not have a specific gen...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04999007 · Jichao Qin Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who are older than 18 years and younger than 85 years old. - People who have been diagnosed with a type of rectal cancer called rectal adenocarcinoma, confirmed by a biopsy or tissue test before surgery. - People for whom surgeons plan a specific type of rectal surgery...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05000697 · Hospital Alemão Oswaldo Cruz Not Applicable · 3 countries Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇦🇷 AR🇧🇷 BR Uruguay

**Who might be able to join this trial:** - Adults aged 18 or older - People whose general health and ability to carry out daily activities meets a certain minimum level (confirm with trial site) - People who have been diagnosed with rectal cancer (a specific type called adenocarcinoma, confirmed by biopsy) where the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05007132 · Dominik Paul Modest Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2029
🇩🇪 DE

**Who might be able to join this trial:** - Adults aged 18 or older who have given their signed consent to take part - People who have been diagnosed with colorectal cancer (cancer of the colon or rectum) confirmed by tissue testing, which has spread to other parts of the body (metastatic), with at least one area of c...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05008809 · Dominik Paul Modest Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 November 2027
🇩🇪 DE

**Who might be able to join this trial:** - People aged 18 or older who have given their written consent to participate. - People who have been confirmed through a tissue biopsy to have colorectal cancer (cancer of the colon or rectum) that is classified as adenocarcinoma. - People whose colorectal cancer has spread (...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05024097 · Weill Medical College of Cornell University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with rectal adenocarcinoma (a specific type of rectal cancer), confirmed through a tissue sample analysis - People who are 18 years of age or older - People who are generally well enough to carry out daily activities with little to no limitatio...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05044689 · Obafemi Awolowo University Teaching Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
Nigeria

**Who might be able to join this trial:** - People in the "Case Group" who have a confirmed diagnosis of colorectal or breast cancer, verified through laboratory tissue testing - People in the "Control Group" who have not been diagnosed with any form of cancer **Who may not be able to join:** - People in the "Contro...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05049317 · Renmin Hospital of Wuhan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 24 September 2022
🇨🇳 CN

**Who might be able to join this trial:** - Men between 18 and 70 years of age who have given their informed consent to participate - People whose tumour is located between 6 and 12 centimetres from the opening of the back passage, as measured by a specialised scope - People who have been diagnosed with rectal cancer c...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05051046 · University Hospital, Tours Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 7 February 2028
🇫🇷 FR

**Who might be able to join this trial:** - Adults aged 18 years or older - People scheduled for a screening colonoscopy, which may be due to a positive bowel cancer screening test, a family or personal history of colon cancer or growths in the bowel, a history of inflammatory bowel disease, or symptoms such as bowel c...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05055635 · University of Aarhus Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 6 July 2027
🇩🇰 DK

Who might be able to join this trial: - People who have anal cancer that has come back after previous treatment - The cancer has been confirmed by a tissue biopsy as a type called squamous cell carcinoma - A radiation treatment plan from the original radiotherapy course is available - The person has previously received...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05064124 · University College, London Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2025
🇬🇧 GB

Who might be able to join this trial: - People who are already scheduled to have a colonoscopy (whether for routine screening, follow-up monitoring, or because they have symptoms). - People aged 18 years or older at the time of signing the consent form. - People who are able to understand, sign, and date the consent fo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05093907 · BeyondBio Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 November 2026
🇰🇷 KR

Who might be able to join this trial: - Adults aged 19 years or older at the time of signing the consent form - People who have been diagnosed with colorectal cancer confirmed by a tissue or cell sample test - People whose colorectal cancer has spread to other parts of the body and cannot be removed by surgery - People...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05136326 · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2023
🇮🇹 IT

**Who might be able to join this trial:** - People aged 18 or older who are willing and able to follow the study procedures and give written consent to participate. - People who are in good general health and able to carry out normal daily activities with little to no limitation (as measured by a standard performance...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05148494 · Nova Scotia Health Authority Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 August 2026
🇨🇦 CA

Who might be able to join this trial: - People who are scheduled to have a type of keyhole surgery performed through the back passage (called transanal endoscopic surgery) at the QEII Health Sciences Center in Halifax, carried out by one of their specialist bowel surgeons Who may not be able to join: - People who have...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05168839 · Centre Hospitalier Universitaire de Besancon Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 October 2025
🇫🇷 FR

**Who might be able to join this trial:** - You are over 18 years old - You are scheduled for a planned (non-emergency) surgery to remove part of the left side of your colon or the upper part of your rectum for cancer, where the two ends of the bowel will be joined back together inside the abdomen - You are willing and...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05174169 · NRG Oncology Phase 3 · 3 countries Recruiting
Recruiting Phase 3 Est. completion 10 March 2029
🇨🇦 CA Puerto Rico🇺🇸 US

Who might be able to join this trial: - People who are in good general health, able to carry out normal daily activities with minimal limitations (rated 0 or 1 on a standard medical fitness scale called ECOG). - People who have been confirmed by lab testing to have Stage IIB, IIC, or Stage III colon cancer (a type call...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05174286 · Columbia University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇺🇸 US

Who might be able to join this trial: - People who speak English - People aged 45 years or older - People who are not currently up to date with colorectal cancer screening - People who have access to a working telephone - People who are able to give informed consent to participate Who may not be able to join: - People...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05179889 · Chungnam National University Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 5 July 2028
🇰🇷 KR

**Who might be able to join this trial:** - You are between 20 and 70 years old and are generally able to carry out daily activities with minimal limitations, OR you are between 71 and 75 years old and fully able to carry out all normal daily activities without any restrictions - Your colon cancer has been confirmed b...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05194878 · Sun Yat-sen University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2024
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with cancer or high-grade pre-cancerous changes in the colon (located higher up in the large bowel, not the lower rectum), confirmed by a tissue sample and/or clear imaging scans. - People whose tumour has a specific genetic profile — tested th...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05197322 · University College, London Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 July 2026
🇬🇧 GB

**Who might be able to join this trial:** - People who have been diagnosed with colon or rectal cancer (confirmed by tissue testing) that has a specific genetic feature called MMR deficiency or MSI-high, detected through laboratory testing. - People who are in good general health (able to carry out normal daily activi...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05201430 · Fudan University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 June 2024
🇨🇳 CN

**Who might be able to join this trial:** - Your rectal cancer has been assessed by MRI scan and is at a stage where it has grown into or through the rectal wall, or has spread to nearby lymph nodes - Your cancer has been confirmed by a tissue sample (biopsy) to be a specific type of rectal cancer called adenocarcinoma...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05217940 · Icahn School of Medicine at Mount Sinai Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇺🇸 US

**Who might be able to join this trial:** - Women who have been diagnosed (confirmed by laboratory testing) with a serious pre-cancerous or cancerous condition of the cervix, vulva, or vagina linked to a virus called HPV — this includes conditions graded as level 2 or higher, or a history of cervical, vaginal, or vulva...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05224518 · National Taiwan University Hospital Hsin-Chu Branch Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇹🇼 TW

**Who might be able to join this trial:** - People aged 21 or older who have been diagnosed with colorectal cancer at an early to non-spreading stage (in situ, Stage I, II, or III) - People who are mentally well and able to think clearly - People who are able to read or speak Mandarin or Taiwanese, as the study materia...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05234177 · Tempus AI Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with, or are suspected to have, a type of bowel cancer called colorectal adenocarcinoma, at stages I through IVA - People who are planning to have, or have already had, surgery to remove a tumour in the colon or rectum with the goal of curing the di...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05254327 · University of Nebraska Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with locally advanced rectal cancer (a specific type called adenocarcinoma) confirmed by a lab test, who are planned to receive a full course of treatment before surgery, with the goal of curing the cancer. - People whose rectal cancer has been...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05257135 · Institut du Cancer de Montpellier - Val d'Aurelle Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2026
🇫🇷 FR

Who might be able to join this trial: - People who are 18 years of age or older - People being treated for colon cancer at the Montpellier Regional Cancer Institute, where surgery is not an option for either the main tumour or any spread of the cancer, whether currently receiving treatment or not - People whose colon c...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05296681 · Howard S. Hochster, MD Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with colon cancer that has spread to other parts of the body, confirmed by a biopsy - People whose doctors are planning to treat them with a second or later round of chemotherapy that includes a drug called irinotecan, starting at a specific do...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05299840 · Oncomedics Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇫🇷 FR

**Who might be able to join this trial:** - People aged 18 years or older - People with suspected metastatic colorectal cancer (cancer that has spread from the colon or rectum to other parts of the body), either at the same time as the original diagnosis or later — but only if a biopsy is needed as part of their usual...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05321134 · University of California, Davis Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2028
🇺🇸 US

**Who might be able to join this trial:** - People who are male or female and aged 18 or older. - Women who either test negative for pregnancy and are not breastfeeding, or who are not able to become pregnant (for example, due to menopause for at least 2 years, a hysterectomy, or bilateral tubal ligation). - Women who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05336539 · Singlera Genomics Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who live permanently in Yangzhou - People aged between 40 and 74 years old (based on the date of birth on their ID card) - People who are able to make their own decisions - People who are willing to complete a colorectal cancer risk factor questionnaire and take part i...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05343013 · M.D. Anderson Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 May 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with colorectal cancer that was confirmed through a tissue sample (biopsy) - You have had surgery to remove your colorectal cancer (with no cancer left behind) at stage II, III, or IV, and have finished all planned treatments aimed at curing the cance...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05346757 · Fundacion Clinic per a la Recerca Biomédica Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2027
🇪🇸 ES

**Who might be able to join this trial:** - People aged 50 to 75 with no special risk factors who have been referred for a colonoscopy as part of bowel cancer screening. - People aged 30 to 80 who have a close family member who has had bowel cancer, and who have been referred for a colonoscopy as part of bowel cancer...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05381792 · Chinese University of Hong Kong Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 December 2024
Hong Kong

Who might be able to join this trial: - You need to be scheduled for a procedure to remove a growth in your large intestine (colon or rectum) using a special camera-guided technique (such as endoscopic mucosal resection or endoscopic submucosal dissection) for either a large pre-cancerous polyp or an early-stage bowel...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05396560 · University of Calgary Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 April 2026
🇨🇦 CA

**Who might be able to join this trial:** - People who are 74 years old or younger - People who have at least one risk factor for bowel cancer that would typically lead to a doctor recommending a colonoscopy, such as: a personal history of low-risk bowel polyps, a personal history of high-risk bowel polyps, or a family...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05401318 · University Hospital, Akershus Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 March 2025
🇳🇴 NO

"Who might be able to join this trial: - People who have been diagnosed with colorectal cancer (confirmed through a lab test of tissue) and are scheduled to have surgery with the goal of curing the cancer, followed by standard medical check-ups. Who may not be able to join: - People who are unable or unwilling to sign...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05405673 · Chinese University of Hong Kong Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 June 2025
Hong Kong

**Who might be able to join this trial:** - People who are scheduled for a planned colonoscopy for colorectal cancer screening, monitoring of previously found polyps, or investigation of symptoms such as anaemia, changes in bowel habits, or abdominal pain - People who are 18 years of age or older - People who have prov...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05411718 · M.D. Anderson Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 November 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with Lynch syndrome, either through a confirmed genetic mutation in one of the DNA mismatch repair genes (MLH1, MSH2/EPCAM, MSH6, or PMS2), or through a personal history of certain bowel growths or cancers that show signs of a mismatch repair p...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05424692 · Peking Union Medical College Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2025
🇨🇳 CN

Who might be able to join this trial: - Adults between 18 and 75 years old, of any gender - People who have been diagnosed with colorectal cancer confirmed by a laboratory tissue or cell test - People with colorectal cancer who have had surgery to remove the cancer and need follow-up treatment afterward, and who have n...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05434026 · Beijing Friendship Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 22 June 2032
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with a type of colon cancer called adenocarcinoma, confirmed by a biopsy - People who are healthy enough to undergo surgery - People who are able to understand the trial and are willing to take part by signing a consent form Who may not be able to...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05438836 · Herlev Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2026
🇩🇰 DK

Who might be able to join this trial: - You have been diagnosed with anal cancer that has been confirmed by a biopsy (a small tissue sample taken and examined in a lab) - Your doctors have determined that radiotherapy (radiation treatment) is suitable for you with the goal of curing the cancer - You are willing and abl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05447923 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2030
🇺🇸 US

**Who might be able to join this trial:** - People who are 45 years of age or older - People with no previous history of colorectal cancer or colon polyps - People who have no close family members (parents, siblings, or children) diagnosed with colorectal cancer before the age of 60 - People who are not currently exper...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05462613 · Centre Hospitalier Universitaire de Besancon Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 November 2029
🇫🇷 FR

Who might be able to join this trial: - People who have been diagnosed with colorectal cancer that has spread to other parts of the body, confirmed by a tissue sample (biopsy), and whose cancer has continued to grow after one round of chemotherapy treatment. - People whose first treatment for their spreading cancer inc...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05464030 · EMD Serono Research & Development Institute, Inc. Phase 1 · 5 countries Recruiting
Recruiting Phase 1 Est. completion 23 October 2026
🇨🇦 CA🇯🇵 JP🇰🇷 KR🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with locally advanced or metastatic colorectal cancer (cancer that has spread beyond the colon or rectum), confirmed by a tissue sample, and whose cancer has stopped responding to or who could not tolerate standard treatments — and, where appli...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05485077 · Singlera Genomics Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 9 July 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who are 40 years of age or older - People who are able to make their own decisions and give informed consent - People who are able to complete a colorectal cancer risk factor questionnaire and take part in yearly follow-up interviews after joining - People who are able...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05491434 · Hospital Universitari de Bellvitge Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2025
🇪🇸 ES

**Who might be able to join this trial:** - You are 70 years old or older - You have been diagnosed with a type of colon cancer called adenocarcinoma that has not spread to other parts of the body - Your surgery is not needed as an emergency - You are reasonably active and able to care for yourself to a moderate degree...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05495776 · State Scientific Centre of Coloproctology, Russian Federation Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2025
🇷🇺 RU

Who might be able to join this trial: - People who are willing and able to provide written consent to participate - People who have been diagnosed with colon adenocarcinoma (a type of colon cancer) confirmed by a tissue sample, or people who have been diagnosed with two cancers occurring at the same time and have not y...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05496491 · Larissa University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 August 2026
🇬🇷 GR

**Who might be able to join this trial:** - People who have been diagnosed with rectal cancer (a specific type called adenocarcinoma), confirmed through a tissue sample (biopsy) - People whose cancer has reached certain stages of spread within or around the rectum, based on specific scan findings (confirm with trial s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05513716 · The Christie NHS Foundation Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 3 July 2025
🇬🇧 GB

Who might be able to join this trial: - People aged 18 or older who have been diagnosed with colorectal cancer that has spread to the lining of the abdomen (known as peritoneal metastases) - People who have had a specific type of surgery to remove as much cancer as possible (called cytoreductive surgery) at The Christi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05523245 · Sixth Affiliated Hospital, Sun Yat-sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have a clinical suspicion of rectal cancer, or who have had a colonoscopy showing signs of rectal cancer - People who are over 18 years of age - People who have given their informed consent by reading and signing a consent form **Who may not be able to join:** - P...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05524428 · Massachusetts General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

Who might be able to join this trial: - People who are 18 years of age or older and work as staff members at one of the partnering clinic sites listed in the trial locations. - Staff members whose roles include administrative leadership, population health management, data analysis, quality improvement, nursing, nurse m...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05528783 · Sun Yat-sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2026
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with colorectal cancer (a specific type called adenocarcinoma) confirmed by a lab test - You are between 18 and 80 years old (any gender) - You are scheduled to have surgery to fully remove your colorectal cancer - You have not received any cancer trea...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05529615 · Peking University Cancer Hospital & Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2029
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 75 years old - You have been diagnosed with colon cancer (a specific type called adenocarcinoma) confirmed by a tissue sample test - After surgery, your cancer was found to be at a stage II with certain higher-risk features, or stage III — stage II with...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05536089 · Singlera Genomics Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2028
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with stage I or stage II colorectal cancer (without high-risk features), confirmed by laboratory testing of tissue. - People aged 18 or older at the time of signing the consent form, of any gender. - People who are scheduled to have surgery to remov...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05556473 · Barbara Ann Karmanos Cancer Institute Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 December 2027
🇺🇸 US

Who might be able to join this trial: - You must be 18 years old or older. - The tumor being studied must be at least 1 cm (about half an inch) across, as seen on a scan. - You must be able to lie still in a PET/CT scanner for at least 70 minutes. - You must have had a recent scan (such as an MRI or CT) that shows the...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05566249 · Samsung Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2024
🇰🇷 KR

Who might be able to join this trial: - People aged between 18 and 80 years old, either male or female - People who have had a biopsy confirming a type of cancer called adenocarcinoma - People whose cancer is located in the rectum or at the junction where the rectum meets the sigmoid colon - People whose cancer is the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05568420 · Memorial Sloan Kettering Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇺🇸 US

**Who might be able to join this trial:** *Colorectal Cancer Group:* - People aged 18 to 49 years old - People who have been diagnosed with a type of colorectal cancer called colorectal adenocarcinoma, confirmed by a lab test - People who are scheduled for, or have already had, surgery, a biopsy, or a colonoscopy (inc...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05571644 · Sun Yat-sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 70 years old - People who have been diagnosed with colorectal adenocarcinoma (a specific type of bowel cancer), confirmed by tissue testing - People whose general health and ability to carry out daily activities meets a specific functional standard (known a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05572801 · Aarhus University Hospital Not Applicable · 4 countries Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇩🇰 DK🇫🇮 FI🇳🇴 NO🇸🇪 SE

Who might be able to join this trial: - People diagnosed with squamous cell carcinoma of the anal canal (a type of anal cancer) who are scheduled to receive radiotherapy, with or without chemotherapy, as their main treatment - People aged 18 years or older - People who have given their agreement to take part, both in w...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05576480 · Ruijin Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2025
🇨🇳 CN

**Who might be able to join this trial:** - Adults between 18 and 75 years of age - People who are generally well enough to carry out light activity and care for themselves (a measure doctors use called ECOG score 0–1) - People who have been diagnosed with rectal cancer (a specific type called adenocarcinoma) confirme...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05577143 · University Hospital, Lille Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2027
🇫🇷 FR

**Who might be able to join this trial:** - People who are suspected of having colorectal cancer and for whom a colonoscopy has been recommended by their doctor. - People between 50 and 75 years old who have no current digestive symptoms, and for whom a follow-up colonoscopy has been recommended (for example, as part o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05579353 · Jingbo Chen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2025
🇨🇳 CN

Who might be able to join this trial: - People aged between 18 and 80 years old. - People with a BMI (a measure of body weight relative to height) between 18.5 and 27.9. - People whose planned surgery is one of the following: removal of rectal cancer, removal of right colon cancer, removal of left colon cancer, or remo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05612347 · Dartmouth-Hitchcock Medical Center Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 31 May 2030
🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - People who speak English or Spanish - People who have a personal history of colorectal polyps (growths found in the large intestine) - People whose most recent colonoscopy found 2 or fewer polyps that were not classified as advanced - People who are currently due, or will be...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05628038 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2024
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years old at the time of signing the consent form. - People with a good general health and activity level, rated at 0 or 1 on a standard medical scale (meaning fully active or able to carry out light work). - People whose cancer has come back in the pelv...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05630794 · National Cancer Institute (NCI) Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 May 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are considered high risk for recurring colorectal polyps (adenomas), meaning they have been diagnosed with Familial Adenomatous Polyposis (FAP), OR had more than 5 small polyps (under 1 cm) found on a colonoscopy in the past 5 years, OR had 3 or more polyps with a...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05646511 · National Cancer Center Hospital East Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2029
🇯🇵 JP

Who might be able to join this trial: - People who have given written consent after having the study fully explained to them - People who have been confirmed through a tissue test (biopsy) to have rectal adenocarcinoma (a specific type of rectal cancer) - People whose cancer has not spread to distant parts of the body,...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05655494 · University of Florida Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2027
🇺🇸 US

Who might be able to join this trial: - You are between 18 and 100 years old - You can read English or Spanish at around an eighth-grade level or higher - You come from a racial or ethnic background that has historically been underrepresented in cancer research, such as Black or African American individuals, or Hispani...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05655780 · Maastricht University Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2025
🇳🇱 NL

**Who might be able to join this trial:** - People aged 18 or older - People diagnosed with colorectal cancer (bowel cancer) that has spread or cannot be surgically removed, and who will be treated with a chemotherapy drug called irinotecan, with or without an additional targeted therapy - People whose overall health a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05663203 · Emory University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇺🇸 US

Who might be able to join this trial: **For patients:** - Adults aged 18 or older - Have been diagnosed with colorectal cancer - Expected to live for more than 12 months - Currently receiving chemotherapy treatment - Are experiencing at least two symptoms affecting mood, thinking, or energy (such as fatigue, depressio...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05672524 · Memorial Sloan Kettering Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 July 2027
🇺🇸 US

Who might be able to join this trial: - People who are willing and able to sign a written consent form for the trial. - People who are 18 years of age or older at the time of signing the consent form. - People who are generally well enough to carry out daily activities with little or no limitation (a performance level...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05673148 · Alliance for Clinical Trials in Oncology Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 3 July 2028
🇨🇦 CA🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with colorectal cancer that has spread to other parts of the body (metastatic), confirmed by a tissue sample. - People whose cancer does not have a specific genetic marker called microsatellite instability (MSI) (confirm with trial site). - People w...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05676190 · ShiCang Yu Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 70 years old - People who have been diagnosed with colorectal cancer at stage III or stage IV - People who have at least one tumour or lesion outside the brain that can be measured using standard imaging criteria - People whose cancer has stopped r...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05686499 · Obafemi Awolowo University Teaching Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
Nigeria

Who might be able to join this trial: - Adults who are 18 years of age or older - Healthcare professionals working as consultants or registrars in medicine, surgery, or gastroenterology Who may not be able to join: - People who are under 18 years of age - People who are not willing to sign a consent form Important: A...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05689775 · Oslo University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2024
🇳🇴 NO

Who might be able to join this trial: - People who have been diagnosed with rectal or anal cancer - People who are scheduled to have a robot-assisted surgery to remove the rectum and surrounding tissue (a procedure called abdominoperineal resection) - People whose surgery plan includes rebuilding the pelvic floor and/o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05691491 · National Cancer Institute (NCI) Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with advanced cancer that has spread to other parts of the body, confirmed by a lab test on a tissue or cell sample. - During the dose-finding stage, people with a solid tumour that either has a specific gene marker called MGMT promoter hyperme...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05696002 · Glasgow Royal Infirmary Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2028
🇬🇧 GB

Who might be able to join this trial: - You have had surgery to remove cancer in the pelvic area (the lower part of your abdomen/hip region) where more than one organ in that area was removed during the operation. Who may not be able to join: - No specific exclusion criteria have been listed for this trial (confirm wi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05704010 · San Raffaele University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇮🇹 IT

Who might be able to join this trial: - People who have an inherited genetic change (called a pathogenic germline variant) in one of four specific DNA repair genes — MLH1, MSH2/EPCAM, MSH6, or PMS2 — which are linked to a condition known as Lynch syndrome Who may not be able to join: - People under 18 years of age - P...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05713903 · Larissa University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 January 2027
🇬🇷 GR

**Who might be able to join this trial:** - People who have been diagnosed with cancer in the right side of the colon (specifically the cecum, ascending colon, or hepatic flexure), confirmed by a tissue sample test - People whose surgery will follow a specific surgical technique called Complete Mesocolic Excision (CME)...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05715255 · University of Arizona Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2027
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older - People who have started immunotherapy (a type of cancer treatment) within the past 12 weeks - People who are mentally alert and aware of who they are, where they are, and what time it is, as assessed by the recruiting team - People who can speak and unde...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05719558 · Astellas Pharma Global Development, Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 April 2030
🇺🇸 US

**Who might be able to join this trial:** - People who have an advanced solid tumour cancer that has spread or cannot be removed by surgery, confirmed by pathology records or a current biopsy. - For the single-drug (monotherapy) part of the trial, people with one of these cancer types may be considered: certain types...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05725200 · Oslo University Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2038
🇳🇴 NO

**Who might be able to join this trial:** **Pre-screening stage:** - People who have been diagnosed (confirmed by laboratory testing of tissue) with advanced or metastatic bowel or rectal cancer that has spread and cannot be surgically removed - People who are currently receiving or have previously received treatment...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05731726 · Zhejiang University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing and able to sign a written consent form agreeing to take part. - Adults aged 18 to 75 years old. - People who have been confirmed through a tissue or cell sample test to have a type of rectal cancer called adenocarcinoma. - People who have not previous...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05752136 · Sir Run Run Shaw Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 April 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to receive treatment before surgery (called neoadjuvant therapy). - You are 18 years old or older. - Your tumor is located in the rectum, no more than 12 cm from the opening of the anus, confirmed by physical exam, colonoscopy, and MRI scan. - Your cancer has...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05768503 · Sun Yat-sen University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 January 2026
🇨🇳 CN

Who might be able to join this trial: - People diagnosed with colorectal cancer (specifically adenocarcinoma) that has spread or cannot be surgically removed, confirmed by tissue or cell testing. - People whose cancer has been tested and confirmed to be of a specific type called "pMMR/MSS or MSI-L," meaning the cancer...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05772481 · Centre Paul Strauss Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 18 September 2026
🇫🇷 FR

**Who might be able to join this trial:** - People with a general health status rated as good to moderately functional (ECOG score of 0, 1, or 2) - People with rectal cancer that has been confirmed through tissue testing (biopsy) - People whose cancer meets specific staging criteria — either the tumour has grown into s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05773144 · AdventHealth Translational Research Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years old or older - You have been diagnosed with stage II or III colon cancer, confirmed by a tissue test (biopsy) - You have already had surgery to remove the cancer with the goal of curing it - You are planning to start chemotherapy - You currently do less than...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05793554 · Mater Misericordiae University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2027
🇮🇪 IE

**Who might be able to join this trial:** - You have a rectal polyp or tumour that is larger than 2cm and are due to have surgery or a medical assessment, or your doctor suspects you may have one - You have been diagnosed with rectal cancer and are due to have surgery or a medical assessment, including if you have alre...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05797467 · Sixth Affiliated Hospital, Sun Yat-sen University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 April 2030
🇨🇳 CN

**Who might be able to join this trial:** - People of any sex, aged between 18 and 75 years old - People who have had surgery and whose tissue sample has confirmed a specific stage of colorectal cancer (called pT3-4N2 colorectal adenocarcinoma) - People whose overall physical health and ability to carry out daily activ...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05803382 · National Cancer Institute (NCI) Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 June 2027
🇺🇸 US

**Who might be able to join this trial:** - People taking part in the dose escalation phase must have a laboratory-confirmed cancer that has spread or cannot be surgically removed, and that has continued to grow after standard treatments that included the drugs fluorouracil (5-FU) or capecitabine. - People with colore...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05838391 · Columbia University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed through a tissue biopsy with a specific type of anal canal cancer (squamous, basaloid, or cloacogenic carcinoma) - People whose cancer meets certain size or spread criteria based on medical staging — specifically a tumour larger than 4 cm, or ca...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05848609 · Universitair Ziekenhuis Brussel Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇧🇪 BE

**Who might be able to join this trial:** - People aged 70 years or older who have been diagnosed with colorectal cancer - People who a medical team (multidisciplinary board) has assessed as suitable for colorectal surgery, and who have given their consent to have the surgery **Who may not be able to join:** - People...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05854498 · University of Wisconsin, Madison Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2028
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older. - People who are generally able to carry out daily activities and are either fully active or able to carry out light work (this is measured using a standard scale called the ECOG scale, with a score of 0 or 1). - People who have been diagnosed with c...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05879783 · Nanfang Hospital, Southern Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 September 2023
🇨🇳 CN

Who might be able to join this trial: - People aged 18 to 84 years old - People who have been assessed by an anaesthesiologist as being in a generally healthy to mildly-to-moderately compromised health state before surgery (known as ASA class I, II, or III — confirm with trial site if unsure) - People who have been dia...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05883800 · Haukeland University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇳🇴 NO

Who might be able to join this trial: - People diagnosed with advanced rectal cancer (a type of cancer in the last part of the large intestine) that has spread to nearby tissues or lymph nodes in specific ways, such as growing into surrounding structures, being very close to certain surgical margins, spreading to parti...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05894694 · Guang'anmen Hospital of China Academy of Chinese Medical Sciences Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 30 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with advanced colorectal cancer (confirmed by lab testing) and are receiving your first round of treatment for this advanced cancer - You are 18 years of age or older (any gender) - You are reasonably active and able to care for yourself, with only mil...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05903885 · University of Nebraska Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇺🇸 US

**Who might be able to join this trial:** - People who identify as Black or African American - People between 45 and 75 years old - People who are not current with recommended colorectal cancer screening (confirm with trial site for specific guidelines) - People who are willing to provide contact details for follow-up...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05904665 · Fudan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 July 2025
🇨🇳 CN

**Who might be able to join this trial:** - Adults aged 18 or older, of any gender - People whose general health and ability to carry out daily activities meets a certain minimum level, as measured by standard scoring tools used by doctors (confirm with trial site) - People whose scans before surgery showed no clear s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05908643 · Neogap Therapeutics AB Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇸🇪 SE

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with colorectal cancer (bowel cancer that has spread), confirmed by a tissue or cell sample - Your cancer has spread to other parts of the body (stage 4), and you have either tried all standard treatments available,...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05913674 · Ciusss de L'Est de l'Île de Montréal Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2028
🇨🇦 CA

**Who might be able to join this trial:** - Adults aged 18 or older, of any gender - People who are in good general health, with a performance score showing they are fully active or have only minor restrictions on physical activity (ECOG score of 0 or 1) - People who have been diagnosed through a tissue biopsy with ca...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05914389 · Second Affiliated Hospital, School of Medicine, Zhejiang University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2025
🇨🇳 CN

Who might be able to join this trial: - People aged 18 to 75 years old. - People who have been diagnosed through lab testing with a specific type of colon cancer called MSS or pMMR-type colon adenocarcinoma. - People whose tumor is located more than 12cm from the anus (measured by a camera scope exam), and where the tu...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05914766 · Massachusetts General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 21 May 2028
🇺🇸 US

Who might be able to join this trial: - You are 18 years of age or older - You have been recently diagnosed with locally advanced rectal cancer (stage II or III) and a decision has been made within the last 8 weeks to treat it with more than one type of treatment - You are able to complete the study activities in Engli...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05916040 · Universitair Ziekenhuis Brussel Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2025
🇧🇪 BE

**Who might be able to join this trial:** - People who have been diagnosed with rectal cancer that has grown locally into surrounding tissues but has not spread widely (known as locally advanced rectal cancer) **Who may not be able to join:** - People whose cancer has spread to other parts of the body in a way that ca...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05927584 · Fundación de Investigación Biomédica - Hospital Universitario de La Pr... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2027
🇪🇸 ES

Who might be able to join this trial: - Adults aged 18 years or older. - People who have been confirmed by tissue testing to have a type of rectal cancer called infiltrating rectal adenocarcinoma. - People whose tissue testing showed a rectal polyp or very early-stage cancer, but where additional tests (camera examinat...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05929365 · Military University Hospital, Prague Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇿 CZ

Who might be able to join this trial: - People who have had a colorectal polyp larger than 10mm removed during a colonoscopy using a therapeutic removal technique - People who have signed a consent form agreeing to take part in the study and to undergo colonoscopy Who may not be able to join: - People who have been di...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05929820 · Cedars-Sinai Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 22 September 2026
🇺🇸 US

Who might be able to join this trial: - People who are between 45 and 75 years old - People who have never been screened for bowel cancer (colorectal cancer), or whose bowel cancer screening is no longer current - People who are not considered high risk for bowel cancer (for example, people who do not have inflammatory...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05933122 · University Hospital, Limoges Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
🇫🇷 FR

Who might be able to join this trial: - Women who have been diagnosed with stage I, II, or III rectal cancer or cancer at the junction of the rectum and sigmoid colon - The cancer's surgical join (anastomosis) must be located less than 15 cm from the anal opening - People who have had surgery to remove the cancer, with...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05939401 · Sahlgrenska University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇸🇪 SE

Who might be able to join this trial: - People who have been recently diagnosed with anal cancer for the first time, or whose anal cancer has come back after previous treatment Who may not be able to join: - People who do not have a diagnosis of anal cancer - People for whom taking a tissue sample (biopsy) or blood sa...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05939661 · Osaka University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 March 2026
🇯🇵 JP

**Who might be able to join this trial:** - People who have been fully informed about the study and have provided written consent to participate. - People whose rectal cancer has been confirmed as adenocarcinoma (a specific type of cancer) through tissue testing. - People whose cancer has not spread to distant parts o...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05943444 · Sixth Affiliated Hospital, Sun Yat-sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 8 August 2027
🇨🇳 CN

**Who might be able to join this trial:** - Adults between 18 and 75 years old (men or women) - People who have been diagnosed with rectal cancer before surgery, where the tumour is located very close to the lower part of the rectum (within 3cm of a specific internal landmark, as measured by MRI) - People who do not ha...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05947838 · M.D. Anderson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed (confirmed by lab testing of tissue or cells) with a moderate or poorly differentiated cancer of the appendix or colon/rectum that was initially considered treatable with surgery. - People whose cancer has spread to the lining of the abdomen (perito...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05950503 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 7 June 2026
🇮🇹 IT

Who might be able to join this trial: - People who are older than 18 years of age. - People who have been diagnosed with colorectal cancer confirmed by a tissue sample (biopsy or surgical specimen). - People whose scans (such as a CT scan with contrast dye or a PET-CT scan) have shown that the cancer has spread to the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05954078 · Fudan University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 June 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with colorectal adenocarcinoma (a type of bowel cancer) confirmed through laboratory testing of tissue samples - People who have had surgery to fully remove their primary bowel cancer tumour - People whose cancer is classified as high-risk Stag...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05959356 · Sun Yat-sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years of age or older and are expected to live for at least 12 more weeks - You have been diagnosed with a specific type of colorectal cancer (called RAS and BRAF wild-type, MSS metastatic colorectal adenocarcinoma) confirmed by a tissue or cell sample — this excl...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05962502 · Sun Yat-sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 March 2025
🇨🇳 CN

**Who might be able to join this trial:** - Adults aged 18 or older - People who have been diagnosed with colorectal cancer (a type of bowel cancer) confirmed by a tissue test showing it is an adenocarcinoma (a specific cancer cell type) - People whose cancer started on the left side of the colon or rectum and has spr...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05963191 · PERROD Guillaume Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 18 April 2025
🇫🇷 FR

Who might be able to join this trial: - People who have a confirmed harmful genetic mutation in one of the following genes: MLH1, MSH2, MSH6, PMS2, or EpCAM - People who are of legal adult age at the time their colonoscopy is prescribed - People who agree to take part in the study - People who are enrolled in or covere...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05964530 · National Taiwan University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 19 April 2026
🇹🇼 TW

**Who might be able to join this trial:** - People who have rectal cancer (a specific type called adenocarcinoma) and have completed a course of chemotherapy combined with radiation therapy, with follow-up scans showing no signs of remaining cancer - People whose overall physical health falls within a standard fitness...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05965531 · Sun Yat-sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with rectal adenocarcinoma (a specific type of rectal cancer) confirmed by a biopsy - People whose cancer has been staged before treatment as a locally advanced rectal cancer (stages T3-4N0M0 or T1-4N1-2M0 under an international staging system...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05970302 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2025
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with colorectal cancer that has spread (metastatic) and cannot be surgically removed, and lab tests confirm it is a specific type (MSS/pMMR with a RAS gene mutation) - You are generally active and able to care for yourself, with only mild limitations...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05984485 · Sun Yat-sen University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 July 2028
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years who have been newly diagnosed - People whose rectal cancer has been confirmed by a pathology test (tissue sample analysis) as a type called adenocarcinoma - People whose tumor is located within 15cm of the anal opening - People whose MRI scan shows...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05984589 · University of Southern California Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2027
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years old or older at the time of signing up - You have been diagnosed with Stage I–IV colorectal cancer or another gastrointestinal cancer at some point in the last 10 years - You can speak, read, and write in English well enough to take part in the program - You...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05985109 · Peking University Cancer Hospital & Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are able to understand and voluntarily sign a consent form agreeing to take part in the study. - People who are 18 years of age or older on the day they sign the consent form, of any gender. - People who have been diagnosed with colorectal cancer (a type of bowel...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05985954 · M.D. Anderson Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 28 March 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have signed a consent form agreeing to take part before any screening tests are done (non-English speakers may be eligible with the help of a language assistance service). - People who are 18 years of age or older at the time of signing the consent form. - People...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05988645 · MiWEndo Solutions S.L. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 29 December 2025
🇪🇸 ES

Who might be able to join this trial: - People who have previously had a polyp detected in the rectum and have been referred to have it removed. - People who are able to provide written agreement to take part in the trial. Who may not be able to join: - People who are considered at high risk of serious complications s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05993923 · Centre Hospitalier Universitaire de Nīmes Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2028
🇫🇷 FR

Who might be able to join this trial: - The patient, or someone representing them, must have agreed to take part and signed a consent form after being fully informed about the trial - The patient must be covered by a health insurance plan - The patient must have a confirmed diagnosis of colorectal cancer - The patient...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05994482 · VA Office of Research and Development Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇺🇸 US

**Who might be able to join this trial:** - Veterans who were alive at age 75 at some point between 2005 and 2019, and who had a qualifying colonoscopy in the 10 years before turning 75 - Veterans whose colonoscopy records are in a format that can be read and processed by the study's data system - Veterans aged 75 or...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05999396 · German Cancer Research Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 October 2026
🇩🇪 DE

**Who might be able to join this trial:** - You are willing and able to give written consent to take part and can follow the study requirements, including attending scheduled visits and treatment sessions. - You have colorectal cancer that has spread to other parts of the body (metastatic) and is getting worse, and yo...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06002789 · Sixth Affiliated Hospital, Sun Yat-sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2027
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with multiple separate colorectal cancers occurring at the same time, confirmed by a tissue sample (biopsy) - Lab tests on at least one of your tumors show a specific genetic feature called "mismatch repair deficiency" (dMMR) or "high microsatellite i...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06008119 · Shanghai Kechow Pharma, Inc. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 24 December 2026
🇨🇳 CN

Who might be able to join this trial: - People aged 18 to 70 years old at the time of signing the consent form - People who have been diagnosed with colorectal cancer that has spread to other parts of the body (metastatic), confirmed by a tissue or cell sample - People whose cancer has a specific genetic change called...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06017583 · Yong Zhang,MD Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 August 2024
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 70 years - People whose rectal cancer has been confirmed by a tissue biopsy to be a type called adenocarcinoma - People whose cancer has reached a certain stage of growth or has spread to nearby lymph nodes, but has not spread to distant parts of the body (b...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06043999 · Sun Yat-sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 75 years old - You have had a local surgical removal of a rectal cancer (adenocarcinoma) using one of several specific procedures (such as TEM, TAMIS, EMR, ESD, or polypectomy — confirm with trial site if unsure which applies to you) - Your tumor meets...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06050447 · Immanuel Kant Baltic Federal University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2024
🇷🇺 RU

Who might be able to join this trial: - People who have been diagnosed with a type of bowel cancer called adenocarcinoma, confirmed through laboratory testing of tissue samples - People whose cancer has been reviewed by a specialist medical team who have recommended surgery as the appropriate treatment - People who are...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06057350 · Norwegian Department of Health and Social Affairs Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 September 2031
🇳🇴 NO🇵🇱 PL

Who might be able to join this trial: - People aged 40 or older who have had a colon polyp or early colon cancer removed by endoscopy (using tools such as a snare, forceps, or tissue removal techniques), where the edges of the removed tissue showed cancer cells very close to or at the margin - The removed cancer was lo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06059963 · Universal Diagnostics Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 October 2026
🇺🇸 US

**Who might be able to join this trial:** - You are between 45 and 84 years old at the time of signing up - You are already scheduled to have a routine screening colonoscopy as part of your normal healthcare - Your doctor or healthcare provider considers you to be at average risk for colorectal cancer - You are willing...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06068257 · University of Central Florida Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2025
🇺🇸 US

Who might be able to join this trial: - Adults who have been diagnosed with breast cancer or colorectal cancer, or adults who have no cancer (referred to as healthy controls) - People who are able to have a blood draw after fasting (going without food for a period of time before the test) - Pregnant women are also welc...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06076811 · University of Aarhus Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 July 2028
🇩🇰 DK

**Who might be able to join this trial:** **Part I – Surgery** - People who have been diagnosed with colon or rectal cancer at an early to intermediate stage (stage I, II, or III) - People who are able to understand and sign a written consent form agreeing to take part - People who are scheduled for surgery with the g...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06082648 · Huashan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 October 2024
🇨🇳 CN

Who might be able to join this trial: - People who have a tumour very low in the rectum and have had a specific type of surgery (called intersphincteric resection) along with a temporary bowel diversion (called a preventive ileostomy). - People who are willing to take part in the study and have signed a consent form ag...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06090994 · Fudan University Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 July 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older, of any gender - People who have been diagnosed with colorectal cancer confirmed by laboratory tissue testing, at stage II (TNM classification) - People who had surgery to fully remove the colorectal cancer (called R0 resection) within the 12 weeks be...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06098560 · Geneplus-Beijing Co. Ltd. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇨🇳 CN

Who might be able to join this trial: - People with advanced or locally advanced colorectal cancer that has a specific genetic feature known as dMMR or MSI-H - People who are expected to receive, or are already receiving, a type of cancer treatment called immune checkpoint inhibitor therapy - People who are in reasonab...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06107920 · University Hospital, Rouen Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 August 2031
🇫🇷 FR

**Who might be able to join this trial:** - Adults aged 18 or older - People who are generally well and able to carry out daily activities with little or no limitation (as measured by a standard health scale used by doctors) - People who have a blockage-causing colon cancer that has been managed with a temporary openi...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06118762 · The First Affiliated Hospital of Nanchang University Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 October 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have fully understood the study and have signed a consent form agreeing to take part - People aged 18 or older, of any gender - People who have been diagnosed with advanced or metastatic colorectal cancer (a type of bowel cancer that has spread), confirmed by a ti...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06121089 · Moscow Clinical Scientific Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2025
🇷🇺 RU

**Who might be able to join this trial:** - People who are at least 18 years old - People whose general health and ability to carry out daily activities falls within an acceptable range for this trial (rated on a standard scale used by doctors — confirm with trial site) - People who have been diagnosed with a specific...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06134388 · Tanta University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 September 2025
🇪🇬 EG

**Who might be able to join this trial:** - People who have been diagnosed with stage 4 (metastatic) colorectal cancer, confirmed through a tissue sample test - People aged between 18 and 65 years old, male or female - Women who could become pregnant must be using an accepted form of contraception - People who are wel...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06136949 · Centro di Riferimento Oncologico - Aviano Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2032
🇮🇹 IT

**Who might be able to join this trial:** - People who have been diagnosed with colorectal cancer (cancer of the colon or rectum), confirmed through laboratory testing of tissue, at any stage of the disease - People aged 18 years or older - People who are willing and able to sign a consent form agreeing to take part -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06149481 · National Cancer Institute (NCI) Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 October 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with colorectal cancer that has spread to other parts of the body, confirmed by a tissue sample test. - People who have already received, were unable to receive, or chose not to receive two standard treatment courses for their cancer (specific drug...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06168786 · Huazhong University of Science and Technology Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 28 February 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have signed a written consent form before any study procedures begin - People aged 18 to 75 years old - People who have been diagnosed with advanced (Stage IV) colorectal cancer, confirmed through a tissue or cell sample - People whose cancer has a specific geneti...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06193356 · University Hospital, Ghent Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2026
🇧🇪 BE

Who might be able to join this trial: - Endoscopists (doctors who perform a type of internal examination using a flexible camera) at any level of experience, from beginners to experts Who may not be able to join: - Adults who do not give their consent to participate in the trial Important: Always verify eligibility w...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06194708 · Peking Union Medical College Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇨🇳 CN

Who might be able to join this trial: - People whose rectal cancer has been confirmed by laboratory testing as a specific type called adenocarcinoma - People whose tumor is located within 12 centimetres of the opening of the rectum (the anus) - People whose primary tumor has been fully removed by surgery - People who r...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06202001 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 September 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who have been confirmed by tissue testing to have a type of bowel cancer called colorectal adenocarcinoma. - People whose colorectal cancer has spread to other parts of the body, as confirmed by CT scan and MRI. - People who have already received a first round of chem...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06202183 · Dana-Farber Cancer Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with early-stage or metastatic colon or rectal cancer - People who were between 18 and 50 years old at the time of their cancer diagnosis - People who do not have major surgery planned in the 12 weeks after joining the trial (having a port plac...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06204484 · Sun Yat-sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who are aged 18 to 70 years old at the time of signing the consent form - People whose general physical functioning is rated as good (scored 0 or 1 on a standard oncology scale), with this rating remaining stable in the 2 weeks before joining, and with an expected sur...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06205485 · Canadian Cancer Trials Group Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 30 January 2030
🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed through a biopsy with a type of rectal cancer called invasive rectal adenocarcinoma that is well or moderately developed (not the most aggressive type), and whose cancer has a normal DNA repair system. - People whose cancer stage, as seen on an...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06205836 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2030
🇺🇸 US

Who might be able to join this trial: **Cohorts A and B (older adults group):** - People aged 70 years or older - People whose general health and ability to carry out daily activities falls within a certain range, as assessed using a standard medical scale (ECOG score of 0–2) - People who have been confirmed through a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06207656 · Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 April 2029
🇪🇸 ES

**Who might be able to join this trial:** - People aged 18 or older at the time of signing the consent form. - People who are able to understand and sign the consent form for the study. - People who are willing and able to attend all scheduled visits, follow the treatment plan, complete lab tests, and follow study pro...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06210971 · Hebei Medical University Fourth Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 February 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 75 years old. - People whose general health and ability to carry out daily activities falls within an acceptable range, based on a standard medical scoring system (called ECOG performance status 0–1). - People who have been confirmed through labora...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06215677 · Peking Union Medical College Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 May 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 75 years old - You are generally able to carry out daily activities, with little or no limitation due to your illness (confirm with trial site) - You have been diagnosed with a specific type of colon cancer (adenocarcinoma) confirmed by a tissue sample,...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06218433 · Tampere University Hospital Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 30 December 2026
🇨🇦 CA🇫🇮 FI

Who might be able to join this trial: - People who are willing and able to give their informed consent to participate - People who have been diagnosed with Lynch syndrome - People who are between 50 and 75 years of age at the time of joining the study Who may not be able to join: - People who currently have a type of...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06218810 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to sign a written consent form agreeing to take part in the study. - People aged between 18 and 75 years old (any gender). - People whose general physical fitness is rated as 0 or 1 on a standard cancer performance scale, meaning they are fully active...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06220058 · Fernandez Zamora Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 January 2026
🇪🇸 ES

Who might be able to join this trial: - People who have been diagnosed with a condition affecting the large bowel or rectum that requires urgent open abdominal surgery through a cut down the middle of the abdomen. - People who start with keyhole (laparoscopic) surgery urgently but need to be switched to open abdominal...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06220617 · Zhejiang University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** **For the "Case" group (people with a diagnosis):** - Adults aged 18 or older - People who have been diagnosed with colorectal cancer or a significant colon polyp (advanced adenoma) confirmed by colonoscopy and tissue testing - People who have agreed to take part by signing a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06226857 · City Clinical Oncology Hospital No 1 Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2026
🇷🇺 RU

**Who might be able to join this trial:** - People who have signed an informed consent form before any trial-related procedures begin. - People aged 18 or older. - People who are reasonably active and able to care for themselves, with only limited physical limitations (this is measured using a standard scale called EC...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06234007 · Union Hospital, Tongji Medical College, Huazhong University of Science... Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2024
🇨🇳 CN

**Who might be able to join this trial:** - People who have given written consent and chosen to take part voluntarily - Adults aged 18 to 75 years old (men or women) - People diagnosed with locally advanced rectal cancer (a specific type called adenocarcinoma), confirmed by a tissue test - People whose pelvic MRI scan...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06242067 · Qilu Hospital of Shandong University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2024
🇨🇳 CN

**Who might be able to join this trial:** - People who have signed an informed consent form before any study procedures begin - People aged 18 to 75 years old, of any gender - People whose general health and ability to carry out daily activities is rated at a good level (ECOG score of 0 or 1), with a life expectancy o...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06242418 · West China Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People between 18 and 75 years of age, of any gender - People whose tumor is located in the colon, where the bottom edge of the tumor is more than 12 cm away from the anus - People who have already had surgery to remove the tumor, and whose cancer was confirmed by laboratory...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06245356 · UNICANCER Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 22 October 2026
🇫🇷 FR

**Who might be able to join this trial:** - People who have given written consent before any trial procedures begin (if someone is physically unable to sign, a trusted person of their choice may confirm consent in writing on their behalf) - People with a confirmed diagnosis of adenocarcinoma of the colon, rectum, lowe...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06252142 · Tata Memorial Centre Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2026
🇮🇳 IN

Who might be able to join this trial: - Adults aged 18 years or older - People who have been diagnosed with locally advanced rectal cancer and have been assessed as suitable for a "watch and wait" approach (where treatment response is monitored rather than proceeding straight to surgery), based on international guideli...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06254521 · First Affiliated Hospital of Guangxi Medical University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 December 2024
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 70 years old. - People who have been diagnosed with a specific type of colon cancer called MSS colon adenocarcinoma, confirmed through laboratory testing (either genetic testing or tissue staining methods). - People whose tumor is located less than 12cm fro...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06270017 · University Hospital, Linkoeping Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2025
🇸🇪 SE

"Who might be able to join this trial: - People who have colon cancer and are scheduled to have surgery to fully remove the cancer from the colon - People who have signed a form agreeing to take part in the trial Who may not be able to join: - People who do not wish to participate in the trial Important: Always verif...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06272461 · University Tunis El Manar Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 February 2026
Tunisia

Who might be able to join this trial: - People aged 18 or older. - People whose overall health before surgery is assessed by an anaesthesiologist as being in a low-to-moderate risk category (known as ASA physical status I, II, or III). - People who are scheduled for a planned (non-emergency) open bowel or colon surgery...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06279351 · Xinqiao Hospital of Chongqing Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with stage IV colorectal cancer (on the left side of the colon) that cannot be removed by surgery, confirmed by lab testing, and your cancer has specific genetic features called "RAS and BRAF wild-type" - You are in generally good physical health and...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06282016 · Bavarian Cancer Registry Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2026
🇩🇪 DE

Who might be able to join this trial: - People who have statutory (government-provided) health insurance and have visited at least one outpatient doctor in Bavaria between 2021 and 2023 - People who live in Bavaria Who may not be able to join: - There are no listed exclusion criteria for this trial Important: Always...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06287671 · Claus Anders Bertelsen, PhD, MD Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇩🇰 DK

Who might be able to join this trial: - People who have been diagnosed with, or are suspected of having, colorectal cancer, bowel polyps (adenoma), inflammatory bowel disease, complications from bowel diverticulosis, or other conditions that require surgical removal of part of the colon or rectum - People who are sched...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06293014 · Henan Cancer Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 October 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to take part voluntarily and agree to follow the study requirements - People aged 18 or older - People who have been diagnosed with colorectal cancer (a specific type called adenocarcinoma) that cannot be removed by surgery, confirmed by a laboratory t...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06293625 · Centre Hospitalier Universitaire Dijon Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 June 2032
🇫🇷 FR

**Who might be able to join this trial:** - People who have been diagnosed with a specific type of colon cancer (adenocarcinoma) confirmed by biopsy, including cancers in the upper part of the rectum if radiotherapy is not needed for that area - People whose cancer has spread to nearby tissue or lymph nodes but not to...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06302751 · Istituto Clinico Humanitas Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 26 February 2026
🇮🇹 IT

Who might be able to join this trial: - People who are over 18 years old. - People who are scheduled for planned (non-emergency) bowel or rectal surgery aimed at treating or removing a condition, such as removal of part of the colon, rectal surgery (with or without a temporary stoma bag), full colon removal, or related...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06307548 · Roswell Park Cancer Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2027
🇺🇸 US

**Who might be able to join this trial:** - You must be 18 years of age or older - You have colorectal cancer that has spread locally or come back, and you are scheduled to have surgery - You are able to have CT and MRI scans - You are well enough to carry out some daily activities (your doctor will assess your general...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06307938 · Helse Nord-Trøndelag HF Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2026
🇳🇴 NO

Who might be able to join this trial: - People who are 18 years of age or older and have been scheduled for a colonoscopy - People who are able to understand and sign a written consent form agreeing to take part in the study Who may not be able to join: - People who are under 18 years old - People who are unable to un...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06308354 · Xijing Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2048
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with colorectal adenocarcinoma (a specific type of bowel cancer), including those with inherited bowel cancer conditions such as Lynch syndrome, familial adenomatous polyposis, Peutz-Jeghers syndrome, juvenile polyposis syndrome, or serrated polypos...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06314022 · Hospital del Rio Hortega Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2026
🇪🇸 ES

Who might be able to join this trial: - People aged 50 to 69 who are part of a colorectal cancer (bowel cancer) screening program and have had a positive stool test result (a test that checks for hidden blood in the stool, with a result above 100ng/ml) - People who have given their written agreement to take part in the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06314958 · City of Hope Medical Center Not Applicable · 3 countries Recruiting
Recruiting Not Applicable Est. completion 18 June 2028
🇨🇳 CN🇪🇸 ES🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with stage II (high-risk) or stage III colorectal cancer, based on a specific internationally used staging system (TNM classification, 8th edition). - People who have gone through the standard tests and treatments recommended by their local medical...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06321081 · Beijing Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 14 February 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with colorectal cancer (a type of bowel cancer) that has spread to other parts of the body - Your cancer has been confirmed through a tissue sample (biopsy) to be a specific type called adenocarcinoma - A blood test...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06327568 · European Institute of Oncology Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 17 June 2026
🇮🇹 IT

Who might be able to join this trial: - Adults aged 18 years or older - People who have been diagnosed through a tissue sample with high-grade abnormal cells in the anal area (AIN2+) or invasive anal cancer - People who have been diagnosed through a tissue sample with low-grade abnormal cells in the anal area (AIN1) -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06328361 · Tampere University Hospital Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇪🇪 EE🇫🇮 FI

Who might be able to join this trial: - People who have been diagnosed with rectal cancer (a type of cancer starting in the rectum) confirmed by a laboratory tissue test - People whose cancer showed a complete response — meaning no signs of cancer were found after initial treatment given before surgery (called neoadjuv...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06333392 · Vestre Viken Hospital Trust Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇳🇴 NO🇸🇪 SE

Who might be able to join this trial: - People who have been referred for a colonoscopy after receiving a positive result from a FIT (bowel cancer stool) screening test at one of the participating screening centres Who may not be able to join: - People who have been diagnosed with colorectal cancer (bowel cancer) with...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06335420 · Odense University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇩🇰 DK

Who might be able to join this trial: - People who have had any type of surgical removal of adenomas (growths in the bowel) larger than 20 mm, or who have had an early-stage bowel cancer (T1) removed by endoscopy (a camera procedure). - People who agree to follow the treatment and follow-up program for this trial. - Pe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06336902 · University of Southern California Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 15 January 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with metastatic colorectal cancer (a type of colon or rectal cancer that has spread to other parts of the body, such as the liver or lungs), confirmed by a lab test, with a specific genetic feature called "microsatellite stable" (MSS) and any K...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06342401 · City of Hope Medical Center Not Applicable · 4 countries Recruiting
Recruiting Not Applicable Est. completion 18 June 2028
🇮🇹 IT🇯🇵 JP🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** - People who were diagnosed with colorectal cancer (at any stage, from Stage I to Stage IV) before the age of 50. - People who went through the standard tests and procedures to diagnose and assess their cancer, and had at least one blood or tissue sample taken before starting a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06350370 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2023
🇨🇳 CN

Who might be able to join this trial: - You have been diagnosed with a primary cancer (a cancer that started there, not spread from elsewhere) in the colon or rectum, confirmed by laboratory testing of tissue. - The surgery you are having or have had meets the specific definition set out in a medical guideline called t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06358430 · M.D. Anderson Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 18 January 2029
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older. - People who are willing and able to give informed consent and follow the study's instructions throughout the trial. - People who have been diagnosed with colorectal cancer (bowel cancer) and, after having their cancer completely remo...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06364579 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2027
🇮🇹 IT

Who might be able to join this trial: - People who are at least 18 years old - People who have squamous cell carcinoma of the anal canal (a specific type of cancer affecting the anal canal) - People whose cancer has spread to a limited extent (described as "low burden of metastatic disease") at the time of diagnosis -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06366841 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2026
🇮🇹 IT

**Who might be able to join this trial:** - You have been diagnosed with locally advanced rectal or anal cancer and are receiving a long course of radiotherapy. - You are receiving treatment that combines both chemotherapy and radiotherapy. - You are able to understand and fill in questionnaires as part of the study. -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06374173 · Hefei TG ImmunoPharma Co., Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 September 2027
🇨🇳 CN

**Who might be able to join this trial:** - Adults aged 18 or older at the time of signing the consent form. - People with a laboratory-confirmed diagnosis of colorectal cancer (CRC) that cannot be surgically removed and has spread locally or to other parts of the body — or, depending on the trial phase, people with o...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06376565 · Jonsson Comprehensive Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2027
🇺🇸 US

Who might be able to join this trial: - People between the ages of 45 and 75 who have been diagnosed with a high-risk neoplasm (an abnormal growth found during bowel screening) in the past 5 years — some of whom had a follow-up colonoscopy and some who did not (for the interview part of the study) - Primary care doctor...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06380101 · University of South Florida Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with rectal adenocarcinoma (a specific type of rectal cancer) confirmed by laboratory testing of tissue - People whose cancer has been assessed by MRI scan as Stage II (cancer has grown into or through the rectal wall but has not spread to nearby ly...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06385418 · The Second Hospital of Nanjing Medical University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2028
🇨🇳 CN

Who might be able to join this trial: - People of Chinese ethnicity aged between 18 and 75 years, male or female - People who have been diagnosed with colorectal cancer confirmed by a tissue biopsy, with a measurable tumour as assessed by standard imaging criteria - People whose general physical fitness and ability to...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06402188 · Averto Medical, Inc. Not Applicable · 3 countries Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
Armenia🇬🇪 GE Uzbekistan

**Who might be able to join this trial:** - People aged 18 to 65 years old at the time of screening, or people aged 66 to 70 years old who have no more than one heart, metabolic, or lung condition for which they are currently prescribed medication. - People who have been diagnosed with cancer of the rectum or the lowe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06405139 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 April 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have fully understood the study, agreed to take part, and signed a consent form. - People aged 18 to 70 years old. - People who are generally well enough to carry out daily activities with little or no limitation (as rated by a standard medical scale called ECOG,...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06405776 · West China Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2024
🇨🇳 CN

Who might be able to join this trial: - People who are at least 60 years old - People whose overall physical health before surgery has been rated by a doctor as falling within a low-to-moderate risk category (ASA physical status I to III) - People whose body weight falls within a healthy range for their height, specifi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06411600 · Vall d'Hebron Institute of Oncology Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2027
🇪🇸 ES

**Who might be able to join this trial:** - People who are 18 years of age or older at the time of signing the consent form - People who have been diagnosed with colorectal cancer that has spread to other parts of the body (metastatic), confirmed by a laboratory test on tissue or cell samples - People whose tumour has...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06412198 · M.D. Anderson Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2029
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with advanced or spreading colorectal cancer that has a specific gene change called KRASG12C, confirmed through laboratory testing of tumour tissue, and who have already received at least one round of chemotherapy for their cancer. - People who...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06425133 · Centre Hospitalier Universitaire de Besancon Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2027
🇫🇷 FR

Who might be able to join this trial: - People who have been diagnosed with colorectal cancer that has spread to other parts of the body (confirmed by a tissue test), and whose cancer has continued to grow after receiving standard treatments, or who are not suitable candidates for those treatments. - People with a lif...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06434597 · Shanghai Pharmaceuticals Holding Co., Ltd Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People diagnosed with advanced colorectal cancer (that has spread or cannot be removed by surgery), or advanced bile duct cancer (that is locally advanced, has come back, spread, or cannot be removed by surgery) - People whose cancer tests positive for a protein called HER2,...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06434896 · UMC Utrecht Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇳🇱 NL

Who might be able to join this trial: - Adults aged 18 or older - People who have given consent to participate in the PLCRC registry, including agreement to extra blood draws, use of tissue samples for research, and being contacted about future research studies - People already enrolled in a related observational study...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06440902 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2028
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with colorectal cancer that has spread to other parts of the body (metastatic), and testing has shown a specific gene change called a RAS mutation in your tumour - You are generally well enough to carry out light activity and care for yourself (rated 0...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06446050 · Shanghai East Hospital Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 December 2026
🇨🇳 CN

Who might be able to join this trial: - People aged 18 years old or younger, of any gender - People diagnosed with colorectal cancer that has spread to other parts of the body or has grown into nearby tissues, confirmed by a tissue or cell sample test - People whose cancer can be measured on scans according to standard...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06447961 · London North West Healthcare NHS Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 18 June 2026
🇬🇧 GB

Who might be able to join this trial: - Adults aged 18 years or older who live in the UK. - People who have been diagnosed with inherited bowel cancer, or who doctors believe may have inherited bowel cancer, and who have been offered a genetic test because of this. - People who are able to understand the study and agre...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06449989 · Blokhin's Russian Cancer Research Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2027
🇷🇺 RU

Who might be able to join this trial: - Adults aged 18 or older, of any gender - People who have been diagnosed with cancer of the colon or rectum, confirmed through laboratory testing of tissue samples - People whose colorectal cancer has spread to the brain, confirmed through laboratory testing of tissue samples - Pe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06455124 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2026
🇨🇳 CN

**Who might be able to join this trial:** - Adults between 18 and 75 years old, of any gender - People whose cancer has been confirmed by laboratory testing to be a type called adenocarcinoma - People whose tumour is located close to the opening of the bowel (within 7 cm) - People who have already had a local surgical...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06485609 · Sun Yat-sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 75 years old - People who have been diagnosed with a type of colon cancer called adenocarcinoma, confirmed by laboratory testing of tissue - People whose tumor is located in a specific part of the large bowel — from the cecum (the start of the larg...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06485713 · First Affiliated Hospital of Wenzhou Medical University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 75 years old, are generally able to care for yourself or do light activity, and are expected to live for more than 3 months - You have been diagnosed with advanced colorectal cancer (a type called adenocarcinoma) confirmed by a tissue biopsy, and your...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06493019 · Dustin Deming Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 April 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older at the time of giving consent. - People who have signed a consent form agreeing to take part and allowing their health information to be used. - People whose general physical health and ability to carry out daily activities meets a certain standard, a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06493565 · Amsterdam UMC, location VUmc Not Applicable · 5 countries Recruiting
Recruiting Not Applicable Est. completion 1 May 2026
🇫🇷 FR🇮🇹 IT🇳🇱 NL🇪🇸 ES🇬🇧 GB

**Who might be able to join this trial:** - People who are 18 years of age or older - People who have had open or keyhole surgery that preserved the sphincter muscle and involved joining parts of the bowel together, where the join is within 15 centimetres of the anal canal - People who can adequately understand the lan...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06493760 · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2025
🇨🇳 CN

Who might be able to join this trial: - You are 18 years of age or older (male or female) - You have been diagnosed with colorectal cancer that has spread to other parts of the body, confirmed by a lab test on a tissue or cell sample - You are generally able to carry out daily activities with little to no limitation (c...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06497985 · Chipscreen Biosciences, Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 May 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who have given written consent to take part in the study. - People aged between 18 and 75 years old. - People who have been diagnosed with colorectal cancer (a type of bowel cancer) that has spread to other parts of the body and cannot be removed by surgery, confirmed...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06502275 · Chang Gung University of Science and Technology Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 September 2025
🇹🇼 TW

**Who might be able to join this trial:** - People who have been diagnosed with colorectal cancer by a doctor. - People aged 60 or older. - People who are able to read and write, or hold a conversation, in Mandarin or Taiwanese. - People who are fully alert and have no mental health or memory/thinking difficulties. - P...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06502704 · Vilnius University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2025
🇱🇹 LT

Who might be able to join this trial: - People who have been referred for a colonoscopy procedure for medical reasons Who may not be able to join: - People who are pregnant - People who have a weakened immune system - People who have previously been diagnosed with a disease of the colon or rectum - People who have had...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06509126 · National Cancer Institute, Naples Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 January 2028
🇮🇹 IT

**Who might be able to join this trial:** - People who have given written consent to take part in the study and its related tests - People who have been confirmed by tissue testing to have colorectal cancer that started on the left side of the colon and has spread to other parts of the body - People whose cancer has s...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06515821 · Firalis SA Not Applicable · 6 countries Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇧🇬 BG🇫🇷 FR🇩🇪 DE🇱🇹 LT🇵🇹 PT🇷🇴 RO

Who might be able to join this trial: **CRC (Colorectal Cancer) Group:** - People aged 18 or older who have been diagnosed with colorectal cancer based on a colonoscopy result - People whose doctor has already decided they need a colonoscopy - People who are willing to have a stool test, colonoscopy, and tissue sample...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06516445 · Huazhong University of Science and Technology Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 28 June 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who have given written consent to take part in the study - People aged between 18 and 75 years old, of any gender - People who have been diagnosed with a specific type of rectal cancer (called pMMR/MSS rectal adenocarcinoma) confirmed by tissue testing - People whose...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06519006 · F. D. Roosevelt University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2025
🇸🇰 SK

Who might be able to join this trial: - You are able to understand and agree to take part in the study by signing a consent form - You are having a keyhole (minimally invasive) surgery to remove part of the lower rectum (bowel) Who may not be able to join: - You do not wish to take part in the study - You want to do p...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06520683 · Sun Yat-sen University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 November 2027
🇨🇳 CN

Who might be able to join this trial: - You have been diagnosed with colorectal cancer that has a specific genetic feature called dMMR and/or MSI-H, and you have had surgery to remove the tumor - Your cancer has been confirmed by a pathologist as Stage II (specifically T3 or T4, with no spread to lymph nodes), AND you...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06522919 · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. I... Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 April 2026
🇮🇹 IT

**Who might be able to join this trial:** - People who are willing and able to sign a written consent form agreeing to take part in the study. - People who have been diagnosed with a specific type of advanced (metastatic) colorectal cancer confirmed by laboratory testing — known as pMMR or MSS mCRC (confirm with trial...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06524245 · Peking University Shougang Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇨🇳 CN

Who might be able to join this trial: - People aged 18 years or older - People who have been diagnosed with colorectal cancer (bowel cancer) at any stage (I through IV), confirmed through a laboratory tissue test - People for whom blood samples can be collected from two specific locations during surgery, as well as a s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06529523 · Memorial Sloan Kettering Cancer Center Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 1 July 2028
Nigeria🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older at the time of signing the consent form - People who are generally well enough to carry out daily activities with little or no limitation (based on a standard medical fitness scale called ECOG, with a score of 0 or 1) - Women who could become pregnant...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06530303 · Essen Biotech Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 10 September 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are between 16 and 90 years old - You have been diagnosed with cancer (primary, returned, or spread to other parts of the body) confirmed by a tissue test - Your doctors expect you to live for more than 3 months - You are reasonably active and able to care for yourself (...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06536127 · Institut Sainte Catherine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 July 2026
🇫🇷 FR

Who might be able to join this trial: - People who are 18 years of age or older - People who have been diagnosed with rectal adenocarcinoma (a specific type of rectal cancer), confirmed through a tissue sample - People whose rectal cancer falls within certain staging categories based on tumour size and lymph node invol...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06538402 · Odense University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 3 July 2028
🇩🇰 DK

**Who might be able to join this trial:** - People who are having a specific type of bowel surgery called an ileal pouch-anal anastomosis (IPAA) — a procedure that creates an internal pouch to replace the rectum — for either ulcerative colitis or a condition called familial adenomatous polyposis (FAP), and whose bowel...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06540326 · Second Affiliated Hospital, School of Medicine, Zhejiang University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 April 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are willing and able to give written consent to take part in the study. - You are a man or woman between 18 and 75 years old. - You have been diagnosed with colorectal cancer (a type of bowel cancer) that has spread to other parts of the body, confirmed by a tissue or ce...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06542835 · University of Arizona Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇺🇸 US

Who might be able to join this trial: - People between the ages of 45 and 64 - People who are due for colorectal cancer screening (a check to look for signs of bowel cancer) - People who have visited the clinic at least once in the last 6 months - People whose primary language is English or Spanish - People who have a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06543836 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 November 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 80 years old. - People with a general health status rated as fully active or able to carry out light work (confirm with trial site for exact rating scale used). - People who have been diagnosed with advanced or returning colorectal cancer (a type o...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06546176 · Ain Shams University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2024
🇪🇬 EG

Who might be able to join this trial: - You are older than 18 years of age - You are of any sex (male or female) - You have been diagnosed with cancer in the rectosigmoid area (the lower part of the large intestine where it meets the rectum) - You have been diagnosed with cancer in the upper part of the rectum Who may...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06549907 · Peking University Cancer Hospital & Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2028
🇨🇳 CN

Who might be able to join this trial: - You have been diagnosed with a specific type of colorectal cancer that has spread (called MSS metastatic colorectal cancer), confirmed by laboratory testing, and it has stopped responding to a type of immunotherapy drug that targets PD1/PDL1 - Alternatively, you have a different...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06560671 · National Taiwan University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇹🇼 TW

Who might be able to join this trial: - Adults who are scheduled to have a colonoscopy procedure Who may not be able to join: - People who are unable to receive health education or who do not wish to take part in follow-up appointments Important: Always verify eligibility with the trial site directly before applying.

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06562140 · University of Pecs Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2025
🇭🇺 HU

Who might be able to join this trial: - Adults aged 18 to 80 years old who have been diagnosed with colorectal or anal cancer Who may not be able to join: - People who have a disease affecting the nerves or muscles (such as muscular dystrophy or similar conditions) - People who have severe conditions present from birt...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06562543 · Takeda Phase 4 · 2 countries Recruiting
Recruiting Phase 4 Est. completion 4 October 2027
Puerto Rico🇺🇸 US

**Who might be able to join this trial:** - People who have given written or electronic consent to take part. - Adults aged 18 years or older, of any gender. - People who have been diagnosed with colorectal cancer that has spread (metastatic colorectal adenocarcinoma), confirmed by a tissue or cell sample, with a docu...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06565052 · Dana-Farber Cancer Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older at the time of joining the trial - People who speak English - People who have been diagnosed with stage II or stage III rectal cancer - People who are planned to receive, are currently receiving, or have just finished pre-surgery treatm...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06566755 · Caigang Liu Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 February 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are able to understand the study and sign a consent form before any study procedures begin - People aged 18 to 75 years old, of any gender - People whose general physical fitness is rated as 0 or 1 on the ECOG scale, meaning they are fully active or have only mino...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06567782 · GlaxoSmithKline Phase 2 · 6 countries Recruiting
Recruiting Phase 2 Est. completion 23 November 2026
🇧🇪 BE🇮🇹 IT🇯🇵 JP🇪🇸 ES🇨🇭 CH🇬🇧 GB

Who might be able to join this trial: - People who have been diagnosed with colon cancer (a specific type called adenocarcinoma) that has not yet been treated. - People whose colon cancer is at a stage where surgery to remove it is possible (specifically classified as clinically T4N0 or Stage III). - People whose tumor...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06568679 · The Netherlands Cancer Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2037
🇳🇱 NL

Who might be able to join this trial: - People who have colorectal cancer (bowel cancer) that has either spread to nearby areas or to other parts of the body - People whose colorectal cancer has been confirmed through a tissue sample examined in a laboratory - People who were between 18 and 49 years old when they were...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06569368 · M.D. Anderson Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 October 2027
🇺🇸 US

Who might be able to join this trial: - People diagnosed with locally advanced rectal cancer (tumours that have grown through the bowel wall or spread to nearby lymph nodes) where the treatment team has decided to use a full course of treatment before surgery. - People who have not previously received chemotherapy drug...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06574087 · PCK Marine Hospital in Gdynia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇵🇱 PL

**Who might be able to join this trial:** - People who have been diagnosed with an HPV-related gynaecological condition, confirmed through a laboratory examination of tissue samples - People from whom tissue samples can be collected from both a gynaecological organ and the anal canal **Who may not be able to join:** -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06575127 · Al-Azhar University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2025
🇪🇬 EG

Who might be able to join this trial: - People who have been diagnosed with colorectal cancer (confirmed by a tissue sample) that cannot be surgically removed or has spread to other parts of the body, whether or not the original tumour is still present - People whose cancer can be measured on scans according to a stand...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06576986 · Federal University of Minas Gerais Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 12 December 2025
🇧🇷 BR

**Who might be able to join this trial:** - You have been diagnosed with a colorectal (bowel or rectal) tumor and are receiving your first cancer treatment - You are 18 years of age or older - You are male or female - You are eligible to receive a chemotherapy medication called capecitabine, either on its own or combin...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06578637 · Abramson Cancer Center at Penn Medicine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2027
🇺🇸 US

**Who might be able to join this trial:** **Part A** - People who have been diagnosed with Familial Adenomatous Polyposis (FAP) — either through genetic testing showing a faulty APC gene, through having a family member with a confirmed APC gene fault and showing signs of FAP, or through a clinical diagnosis confirmed...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06584318 · Capital Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 March 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with colorectal cancer (bowel cancer) and are between 18 and 65 years old. - People whose colorectal cancer is at an early stage — specifically Stage I or Stage II. - People who are able to give their own consent to participate, or who have a le...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06588166 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 August 2026
🇮🇹 IT

Who might be able to join this trial: - You are between 50 and 74 years old and are taking part in the national bowel cancer screening program - You have recently had a positive result on a stool (FIT) test, which checks for hidden blood in your poo - You are able to sign a consent form and are willing and able to foll...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06589388 · Gene Solutions Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇻🇳 VN

Who might be able to join this trial: - People aged 18 or older, of any gender - People diagnosed with stage II or stage III rectal cancer who have been recommended to receive total neoadjuvant therapy (a full course of treatment given before surgery) - People for whom a biopsy tissue sample (preserved in a standard la...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06589440 · Stingray Therapeutics Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2027
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older who have given written consent to participate. - People with a confirmed diagnosis of bowel cancer (colon or rectal cancer) that cannot be removed by surgery and has spread to other parts of the body. - People whose tumour has been tested and found to...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06589830 · Suzhou Teligene Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2026
🇨🇳 CN

Who might be able to join this trial: - People aged 18 or older, of any gender - People diagnosed with HER2-positive, RAS wild-type colorectal cancer that has spread or cannot be removed by surgery, and who have already received specific prior treatments including fluoropyrimidine, oxaliplatin, irinotecan, and a type o...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06609551 · Zhejiang Cancer Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2029
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 70 and 80 years old, both men and women - People who have been confirmed through laboratory tissue testing to have stage II high-risk or stage III colon cancer - People with an ECOG performance score of 2 or less (this is a measure of how much a person's c...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06613113 · Ningbo Medical Center Lihuili Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who are 18 years of age or older, of any gender - People whose general health and ability to carry out daily activities is rated at 0 or 1 on a standard oncology scale (ECOG Performance Status), meaning they are fully active or have only minor limitations - People who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06613165 · Xijing Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 September 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 80 years old, of any gender - People whose rectal cancer (adenocarcinoma) has been confirmed by laboratory testing of tissue or cell samples, and whose cancer has a specific genetic feature called dMMR/MSI-H, at clinical stage II or III - People who have no...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06613581 · Erasmus Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2029
🇳🇱 NL

Who might be able to join this trial: - People who are 21 years of age or older - People who have been diagnosed with colorectal adenocarcinoma (a type of bowel cancer) confirmed by a tissue sample, without the cancer having spread to distant parts of the body, and who had surgery aimed at fully removing the cancer les...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06614647 · University of Aarhus Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 March 2028
🇩🇰 DK

Who might be able to join this trial: - People who have been treated for stage I or low-risk stage II colorectal (bowel) cancer with the goal of curing the disease. - People who are 18 years of age or older. - People who can understand spoken and written Danish. - People who are able to use a digital care guide on a sm...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06614738 · Hospices Civils de Lyon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 17 December 2028
🇫🇷 FR

Who might be able to join this trial: - People aged 18 or older - People who have agreed to participate (or have not objected to taking part) - People who had their colon surgically removed at least 2 years ago as a preventive measure for a hereditary condition called familial adenomatous polyposis (FAP) related to the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06617858 · M.D. Anderson Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 February 2028
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with colorectal (colon or rectal) cancer, confirmed by a tissue or pathology test. - People who have completed all planned treatments aimed at curing their cancer (such as surgery to remove all visible cancer) and currently show no signs of the dise...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06620627 · Natera, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2025
🇺🇸 US

Who might be able to join this trial: - People who are 40 years of age or older at the time of signing the consent form - People who are planning to have a colonoscopy as a routine screening (not because of symptoms) - People who are able to have blood drawn through a needle for research purposes - People who are able...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06628674 · Chang Gung Memorial Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2027
🇹🇼 TW

Who might be able to join this trial: - People diagnosed with Stage I, II, or III rectal cancer. - People who are already aware of their own cancer diagnosis. - People aged 20 years or older. - People who can communicate in Mandarin or Taiwanese. - People who have agreed to take part in an interview and have signed a c...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06633133 · Daping Hospital and the Research Institute of Surgery of the Third Mil... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with rectal cancer, confirmed by a laboratory tissue test (pathology) - People who are 18 years of age or older - People who are having a specific type of rectal surgery that removes the rectum and reconnects the bowel — this includes procedure...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06634875 · Buzzard Pharmaceuticals Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with cancer of the colon or rectum, confirmed by laboratory testing of tissue or cell samples, where the tumour has a specific genetic change called a RAS mutation (in KRAS, NRAS, or HRAS), is classified as "microsatellite stable," and has a tu...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06640166 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2025
🇮🇹 IT

**Who might be able to join this trial:** - People aged 18 or older - People who have a confirmed diagnosis of colorectal cancer (adenocarcinoma type), confirmed through a tissue or cell sample - People who have scans showing the cancer has spread to other parts of the body (metastatic disease) - People whose cancer c...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06641310 · University of Michigan Rogel Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2028
🇺🇸 US

**Who might be able to join this trial:** - People diagnosed with Familial Adenomatous Polyposis (FAP) — either confirmed by a genetic test showing an APC gene mutation, or by a clinical diagnosis involving more than 50 growths (polyps) in the large bowel - People who still have their rectum (the lower part of the lar...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06643793 · Affiliated Hospital of Nantong University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 October 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years old (any gender) - People who have been diagnosed with colorectal cancer confirmed by laboratory tissue or cell testing, with advanced cancer that has spread and cannot be treated with surgery (stage IV) - People who have at least one tumour that c...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06645236 · QIAGEN Gaithersburg, Inc Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2030
🇬🇧 GB

Who might be able to join this trial: - People who agree to take part in the eligibility screening for the related study (Protocol 20210081) will have their tumour tissue tested for a specific gene change called KRAS G12C as part of this performance study. Who may not be able to join: - No separate exclusion criteria...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06646809 · National University Hospital, Singapore Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2024
🇸🇬 SG

Who might be able to join this trial: - People who are 45 years old or older - People who are scheduled for planned (non-emergency) colorectal cancer surgery - People who are able to understand and agree to take part in the trial Who may not be able to join: - People whose colorectal cancer surgery is needed as an eme...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06662786 · Janssen Research & Development, LLC Phase 3 · 22 countries Recruiting
Recruiting Phase 3 Est. completion 15 December 2028
🇧🇪 BE🇧🇷 BR🇨🇦 CA🇨🇳 CN🇫🇷 FR🇩🇪 DE🇭🇺 HU🇮🇳 IN +14 more

**Who might be able to join this trial:** - You have been diagnosed with a type of bowel cancer called adenocarcinoma, located on the left side of the colon or rectum, and the cancer cannot be removed by surgery or has spread to other parts of the body - Your tumour has been tested and does not have changes (mutations...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06663839 · Light Chain Bioscience - Novimmune SA Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 October 2025
🇪🇸 ES

**Who might be able to join this trial:** - Adults aged 18 or older at the time of signing the consent form. - People with a confirmed diagnosis of colorectal cancer (confirmed through a tissue or cell sample). - People whose cancer has spread locally or to other parts of the body, who have already received at least o...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06670495 · Fudan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with anal cancer - People who have not received radiation therapy or chemotherapy before their tissue sample is collected Who may not be able to join: - People who have an HIV infection - People who have a weakened immune system as a result of havi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06678919 · Arbeitsgemeinschaft medikamentoese Tumortherapie Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2034
🇦🇹 AT

Who might be able to join this trial: - People aged 18 or older who have been diagnosed with metastatic colorectal cancer (cancer that has spread beyond the colon or rectum), confirmed through a tissue sample (such as a biopsy) - People who have already received at least 2 previous rounds of treatment for their cancer,...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06685276 · Dai, Guanghai Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who fully understand the study and are willing to sign a consent form agreeing to take part - People aged between 18 and 75 years old - People who have been diagnosed through a tissue biopsy with colorectal cancer (a type of bowel cancer) that cannot be surgically rem...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06689293 · Nottingham University Hospitals NHS Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2027
🇬🇧 GB

Who might be able to join this trial: - People aged 18 or older - People who have been diagnosed with colorectal cancer, confirmed by a tissue sample (biopsy or surgical specimen) - People who have previously had surgery aimed at fully removing their colorectal cancer - People who are already scheduled, as part of thei...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06696768 · National Cancer Institute (NCI) Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been confirmed through laboratory testing to have colorectal cancer (specifically adenocarcinoma) that has spread or cannot be surgically removed, with disease that can be measured on scans. - People whose scans confirming measurable disease were done within...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06697964 · Universitair Ziekenhuis Brussel Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2029
🇧🇪 BE

Who might be able to join this trial: - People who have already had, or are referred in the future for, a High-Resolution Anoscopy (HRA) procedure at UZ Brussel hospital - People who are 18 years of age or older - People who can understand, speak, and write in French, Dutch, or English Who may not be able to join: - T...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06698757 · Yugui Lian Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 November 2027
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with colon cancer or upper rectal cancer (where the tumour is located more than 10 cm from the anal opening), confirmed by a pathology test, and the cancer is at a stage where it has grown into or through the bowel wall and/or spread to nearby lymph...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06709885 · Daping Hospital and the Research Institute of Surgery of the Third Mil... Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 September 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to sign a consent form agreeing to take part in the study - You have colon cancer that scans (CT or MRI) show has grown into the fatty tissue around the colon by more than 5mm, or has spread through the outer lining of the colon or into nearby organs - Your c...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06712095 · Royal Marsden NHS Foundation Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2025
🇬🇧 GB

**Who might be able to join this trial:** - People aged 18 or older who do not currently have active cancer - People who have not previously had surgery to remove part of the colon or rectum - People who carry a confirmed harmful or likely harmful change (variant) in one of the following genes linked to hereditary canc...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06714357 · National Cancer Institute, Naples Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 20 December 2026
🇮🇹 IT

Who might be able to join this trial: **Part 1 (Main Study)** - People aged 18 or older of any sex who are willing to give written consent to take part in the study and related tests - People who have been confirmed through tissue testing to have colorectal cancer (a type of bowel cancer) that has spread to other part...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06714903 · The First Hospital of Jilin University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with colorectal cancer that has spread to other parts of the body (metastatic colorectal cancer), confirmed by both clinical assessment and laboratory/tissue analysis - People between the ages of 35 and 75 (including both ages) - People whose me...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06717880 · Union Hospital, Tongji Medical College, Huazhong University of Science... Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 July 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to give written consent and are able to attend scheduled visits and follow the trial procedures - Men or women between the ages of 18 and 75 - People who have been confirmed through tissue or cell testing to have advanced colorectal cancer - People who...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06718543 · fan li Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 October 2026
🇨🇳 CN

**Who might be able to join this trial:** - You have signed a consent form agreeing to take part in the study. - You are between 18 and 80 years old, of any gender. - Your doctors have confirmed through a tissue sample (biopsy) that you have rectal cancer (a specific type called adenocarcinoma). - Your cancer is at a c...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06718738 · Beijing Immunochina Medical Science & Technology Co., Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 15 August 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years (any gender) with an advanced gastrointestinal tumour confirmed by a tissue test, specifically those with metastatic colorectal cancer where at least two prior standard treatment lines have stopped working or could not be tolerated due to serious s...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06719414 · Sixth Affiliated Hospital, Sun Yat-sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with rectal cancer that has spread to nearby tissues or lymph nodes but can still be surgically removed, confirmed by a tissue sample (biopsy) - People who received treatment (such as chemotherapy or radiation) before their surgery - People who have...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06722183 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2028
🇩🇪 DE

**Who might be able to join this trial:** - People who have given their signed agreement to take part in the trial. - People who are 18 years of age or older at the time of signing consent. - People who have a confirmed diagnosis of colorectal cancer (adenocarcinoma) that cannot be surgically removed and/or has spread...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06728072 · Virginia Commonwealth University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2035
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with stage IV colorectal cancer - People whose cancer can be measured on scans using a standard set of medical measurement rules called RECIST 1.1 - People who are planning to start a first-line chemotherapy regimen based on a drug called 5-flu...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06734156 · Gulbenkian Institute for Molecular Medicine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 2 December 2026
🇵🇹 PT

Who might be able to join this trial: - People who are willing and able to give written agreement to take part in the study - People who live in Portugal - People who are between 40 and 74 years old - People who have recently been diagnosed with colorectal cancer (bowel cancer) and have not yet started any treatment fo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06738173 · Catholic University of the Sacred Heart Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2029
🇮🇹 IT

Who might be able to join this trial: - People aged 50 to 74 who are taking part in the national bowel cancer screening program - People who have received a positive result on their FIT (faecal immunochemical test, a stool sample test used in bowel cancer screening) - People who are able to sign a consent form and foll...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06740357 · Centre Hospitalier Universitaire Dijon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2031
🇫🇷 FR

**Who might be able to join this trial:** - People aged 18 to 80 - People who have been diagnosed with a specific type of rectal cancer (lieberkuhnian adenocarcinoma) confirmed by tissue testing, with a tumour type known as MSS status - People who have received, or are due to receive, a course of pre-surgery treatment...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06741293 · Gulbenkian Institute for Molecular Medicine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 November 2026
🇵🇹 PT

**Who might be able to join this trial:** - People who are able to give written consent and follow the study's procedures - People who live in the Lisbon Metropolitan Area, Portugal - People between the ages of 40 and 74 years old **Who may not be able to join:** - People who are younger than 40 or aged 75 and older -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06746012 · Ohio State University Comprehensive Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** **For patients:** - Adults aged 18 or older - People who have been diagnosed with stage I, II, or III colon or rectal cancer - People who have had surgery aimed at fully removing the cancer (people with rectal cancer who were managed without surgery may also be eligible) - Peo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06749015 · Fudan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2025
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with colorectal cancer (bowel cancer) that has spread to other parts of the body and cannot be removed by surgery, confirmed through a laboratory test of tissue samples - People whose tumor has tested positive for a specific genetic change called th...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06751940 · The First Affiliated Hospital of Nanchang University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with colorectal cancer (bowel cancer) confirmed through a tissue or cell sample - People who have at least one tumour that can be measured on a scan - People aged between 18 and 70 years old, of any gender - People whose cancer has continued to...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06751953 · The First Affiliated Hospital of Nanchang University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with colorectal cancer (bowel cancer) confirmed by a tissue or cell test - People who have at least one tumour that can be measured on a scan - People aged between 18 and 70 years old, of any gender - People whose cancer has continued to grow o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06756672 · National Taiwan University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇹🇼 TW

Who might be able to join this trial: - People who are scheduled for a planned (non-emergency) keyhole surgery on the colon or rectum. Who may not be able to join: - People who have serious heart or lung conditions. Important: Always verify eligibility with the trial site directly before applying.

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06757192 · Massachusetts General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2029
🇺🇸 US

**Who might be able to join this trial:** *For Patients:* - You are between 45 and 54 years old - You are a patient at the health center - You are willing and able to give verbal or written consent to take part *For Health Center Staff:* - You are 18 years old or older - You work at the health center - You are involv...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06765616 · Feng Tian Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who have given written consent before any study procedures begin - Adults aged 18 to 85 years old (male or female) - People who have been diagnosed with a specific type of rectal cancer (rectal adenocarcinoma) confirmed by a tissue sample (biopsy) - People whose recta...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06769828 · Koo Foundation Sun Yat-Sen Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 14 April 2026
🇹🇼 TW

Who might be able to join this trial: - People aged 20 years or older. - People who had surgery for colorectal cancer with the goal of removing all cancer, and who have remained cancer-free for six months or more based on clinical checks and imaging. - People with a blood protein called CEA that is higher than the norm...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06770270 · Second Affiliated Hospital, School of Medicine, Zhejiang University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have agreed to take part voluntarily, have signed a consent form, and are willing to attend follow-up appointments - People aged 18 to 75 years (inclusive), of any gender - People whose rectal cancer has been confirmed by tissue biopsy and MRI scan to be locally a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06773832 · Peking Union Medical College Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People attending a hospital endoscopy centre for a routine colonoscopy screening, either as an outpatient or as someone already admitted to hospital - People aged 18 years or older - People who understand the study details and have signed a consent form agreeing to take part...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06775951 · IRCCS Azienda Ospedaliero-Universitaria di Bologna Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2025
🇮🇹 IT

Who might be able to join this trial: - People who are older than 18 years of age - People who are scheduled to have a colonoscopy (a procedure to examine the inside of the large bowel) as part of their normal medical care, either as a hospital inpatient or as an outpatient - People who have given their informed consen...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06780423 · Hasselt University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 March 2025
🇧🇪 BE

**Who might be able to join this trial:** This trial has three groups. People may be considered for one of the following: **Group 1 – Colorectal cancer patients with cachexia (significant unintended weight loss):** - Adults aged 18 or older - People who have lost more than 5% of their body weight unintentionally in t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06783244 · Victoria Rosberg Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 June 2026
🇩🇰 DK

Who might be able to join this trial: - People who are older than 18 years of age - People who have been diagnosed with colorectal cancer (cancer of the colon or rectum) - People who are scheduled to have robot-assisted surgery with the goal of removing the cancer completely Who may not be able to join: - People with...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06783491 · Maimónides Biomedical Research Institute of Córdoba Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 June 2030
🇪🇸 ES

**Who might be able to join this trial:** - Adults aged 18 to 75 years (people aged 70–75 will be reviewed by a medical committee before being accepted) - People diagnosed with a specific type of bowel cancer (adenocarcinoma) located in the colon, sigmoid colon, or the junction between the rectum and sigmoid colon, th...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06787105 · iOMEDICO AG Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇩🇪 DE

**Who might be able to join this trial:** - People aged 18 years or older. - People who have been diagnosed with metastatic colorectal cancer (cancer of the bowel that has spread to other parts of the body) and whose treating doctor has decided that treatment with a medicine called fruquintinib is appropriate, in line...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06791512 · Jun Huang Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2030
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with cancer of the colon or upper part of the rectum, confirmed through a tissue sample (biopsy). - People whose tumor has been tested and found to have a normal DNA repair system, described as "pMMR" or "microsatellite stable (MSS)", confirmed thro...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06793137 · AC Camargo Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 October 2025
🇧🇷 BR

Who might be able to join this trial: - You are 18 years old or older and have been diagnosed with a type of rectal cancer called adenocarcinoma, located in the middle or lower part of the rectum - Your cancer is either at an advanced local stage, or its position in the rectum means that surgery to remove the rectum an...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06799793 · IRCCS Azienda Ospedaliero-Universitaria di Bologna Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇮🇹 IT

**Who might be able to join this trial:** - People between 50 and 69 years of age who have taken part in a bowel cancer screening program using a stool (poo) sample test - Both men and women are eligible - People whose stool sample test (called a FIT test) came back positive, meaning a certain level of blood was detect...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06802172 · Fred Hutchinson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2029
🇺🇸 US

**Who might be able to join this trial:** - People of any gender - People who self-identify as Alaska Native or American Indian and are eligible for care at the Alaska Native Medical Center (ANMC) - People aged 21 years or older - People with rectal cancer (Stage II, III, or IV if treatment is aimed at cure) confirmed...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06809660 · Poitiers University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 21 January 2031
🇫🇷 FR

**Who might be able to join this trial:** - You have an endoscopy (a camera procedure to look inside your digestive system) either scheduled during your first study visit or planned within the next 18 months. - You have read and signed a consent form after being fully informed about the study. - You are not under any f...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06815406 · Azienda USL Reggio Emilia - IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇮🇹 IT

Who might be able to join this trial: - People who are 18 years of age or older. - People who have been diagnosed with a specific type of flat, spreading growth in the colon or rectum called a Laterally Spreading Tumor - Granular Type (LST-G) that is at least 20mm in size and has been recommended for removal by endosco...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06819280 · Grit Biotechnology Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 27 May 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to take part voluntarily and are able to follow the study requirements, having signed a consent form - People aged between 18 and 70 years old - People who have advanced colorectal cancer that has continued to grow or spread after receiving first-line c...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06822530 · Fred Hutchinson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2030
🇺🇸 US

**Who might be able to join this trial:** **For patients:** - People who are between 45 and 75 years old - People who receive primary care at Harborview Medical Center, University of Washington-Kent-Des Moines, or University of Washington-Federal Way clinics - People who have had an abnormal stool test result (called...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06822634 · NHS Greater Glasgow and Clyde Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 26 June 2026
🇬🇧 GB

**Who might be able to join this trial:** - People who have been diagnosed with rectal cancer (a type of bowel cancer) confirmed by a tissue sample test - People whose cancer has spread into or beyond the rectal wall to a certain extent, and/or have specific higher-risk features such as cancer in nearby blood or lymph...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06824064 · Riboscience, LLC. Phase 2 · 3 countries Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
Puerto Rico🇺🇸 US🇻🇳 VN

Who might be able to join this trial: - People who are at least 18 years old at the time of signing the consent form. - People with advanced, spreading, or worsening colorectal cancer (CRC) who have already tried all standard treatments available for their situation, or who were not able to have those treatments due to...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06827366 · Centre Leon Berard Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 November 2027
🇫🇷 FR

Who might be able to join this trial: - People who have read the participant information and agreed to take part - People who are willing and available to commit to the full one-year duration of the trial - People who are considered at high risk for colorectal cancer but have tested negative for it - People who are enr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06831669 · Chang Gung Memorial Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 12 December 2028
🇹🇼 TW

Who might be able to join this trial: - People who have been diagnosed with rectal cancer (a type of cancer in the rectum) confirmed through a tissue sample test - People who are planned to receive a full course of treatment before surgery, which combines chemotherapy and radiation therapy Who may not be able to join:...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06831981 · University Hospital Tuebingen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2036
🇩🇪 DE

**Who might be able to join this trial:** - People who have been diagnosed with rectal cancer (confirmed by tissue testing) where the tumour is located in the lower or middle part of the rectum, within 12 cm of the skin opening of the anus - People who are already recommended to receive the type of treatment called to...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06834126 · City of Hope Medical Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 19 September 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have given written consent to participate (or whose legal representative has done so on their behalf) - People who are willing to take part in all related study procedures, including brain scans (fMRI), tissue samples from the tumour and normal rectum, blood draws...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06841159 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years old at the time of signing the consent form. - People with a good general health and activity level, rated 0 or 1 on a standard medical scale (ECOG), meaning fully active or able to carry out light work (confirm with trial site). - People whose col...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06850103 · First Affiliated Hospital of Zhejiang University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have given written consent to take part and are able to attend the required visits and follow the study procedures. - People aged between 18 and 75 years. - People who have been diagnosed with primary rectal cancer (a specific type called adenocarcinoma), confirme...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06853496 · Eiji Shinozaki Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 March 2027
🇯🇵 JP

Who might be able to join this trial: - People who have been diagnosed with colorectal cancer confirmed through a tissue or cell sample analysis - People whose colorectal cancer cannot be surgically removed or has come back, and whose cancer has stopped responding to standard treatments or who cannot tolerate those tre...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06854679 · Royal Marsden NHS Foundation Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 13 January 2027
🇬🇧 GB

Who might be able to join this trial: - People aged 18 years or older - People who have been diagnosed with locally advanced rectal cancer (a type of bowel cancer) confirmed by a tissue sample, where treatment guidelines recommend a combination of chemotherapy and radiotherapy before surgery - People whose overall heal...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06862115 · Kasr El Aini Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 January 2026
🇪🇬 EG

Who might be able to join this trial: - Adults over 18 years old, of any sex - People with a physical health status rated as ASA 2 or 3 (meaning people with mild to moderate ongoing health conditions — confirm with trial site if unsure which category applies) - People who have had high blood pressure for more than 3 mo...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06864338 · Mainz Biomed Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2025
🇺🇸 US

**Who might be able to join this trial:** This trial has two separate groups. A person may be eligible for one or both groups depending on their situation. **Group 1 – Screening Group** - People of any sex who are 45 years of age or older - People who have been advised by their doctor to have a colonoscopy for scree...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06865638 · Nanchong Central Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2029
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with colorectal cancer (confirmed by a tissue test) and your doctors have planned surgery as part of your treatment. - You are between 18 and 85 years old. - Your overall health before surgery has been assessed as acceptable for anaesthesia (rated as A...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06867822 · University of Alabama at Birmingham Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 July 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older at the time of signing the consent form. - People who have been diagnosed with colorectal cancer (a type of cancer that starts in the colon or rectum), confirmed by a tissue or cell sample. - People whose colorectal cancer has spread t...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06869096 · Nanchong Central Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People between 18 and 85 years of age - People whose colorectal (bowel) tumor has been confirmed by CT or MRI scan and is considered removable by surgery - People with a general health and activity level rated as fully active or able to carry out light work (performance statu...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06880055 · Guardant Health, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2030
🇺🇸 US

**Who might be able to join this trial:** - People aged 45 to 81 years old at the time of signing the consent form - People who are planning to have a standard Shield test (a type of bowel cancer screening test) - People considered by their doctor or healthcare provider to be at average risk for bowel cancer — meaning...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06881537 · Shanghai Changzheng Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2025
🇨🇳 CN

**Who might be able to join this trial:** - You had colorectal cancer that was surgically removed (with all cancer tissue fully removed), confirmed by lab testing to be a specific type called adenocarcinoma, and you received standard chemotherapy after surgery. - Your cancer has come back in the same local area, confi...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06885385 · Shanghai Junshi Bioscience Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 27 November 2026
🇨🇳 CN

**Who might be able to join this trial:** - Adults between 18 and 75 years old (inclusive), of any gender - People diagnosed with a specific type of colorectal or rectal cancer (adenocarcinoma) confirmed by laboratory testing, classified as stage IV, and identified as a particular molecular subtype called MSS or pMMR...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06887218 · The Methodist Hospital Research Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2028
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older of any gender. - People with colorectal cancer that has spread to other parts of the body, confirmed by a tissue or cell sample test. - People whose cancer has continued to grow or spread after trying two previous lines of treatment for metastatic disease....

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06887244 · National Cancer Institute, Naples Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2025
🇮🇹 IT

**Who might be able to join this trial:** - People who are scheduled for a full colonoscopy (an examination of the entire large intestine) as an outpatient procedure - People having the colonoscopy for diagnostic reasons (to investigate a problem) - People having the colonoscopy for screening reasons (a routine check)...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06889883 · ADVANCED MARKER DISCOVERY S.L. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇪🇸 ES

Who might be able to join this trial: - People aged 18 or older who are able to understand the participant information and sign a consent form. - People who are scheduled to have a colonoscopy or surgery to remove a colorectal tumour. Who may not be able to join: - People who have had any type of cancer in the 5 years...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06898996 · University of Chicago Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2029
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with Lynch Syndrome (LS) and have a confirmed harmful change (pathogenic variant) in one of these genes: MLH1, MSH2, MSH6, PMS2, or EPCAM. - People aged 20 to 80 years old who have a harmful variant in the MLH1, MSH2, or EPCAM gene. - People ag...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06903858 · Sun Yat-sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 April 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who have given written consent and are willing to follow the study procedures - People aged 18 or older - People who have been diagnosed with colorectal adenocarcinoma (a specific type of bowel cancer), confirmed through laboratory testing of tissue - People whose can...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06907342 · St. Olavs Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇳🇴 NO

Who might be able to join this trial: - Adults aged 18 or older - People who are generally well enough to carry out daily activities with little or no limitation (as measured by a standard medical scale called ECOG, scoring 0 or 1) - People who have given their written agreement to take part in the trial - People whose...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06911970 · Université de Sherbrooke Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2026
🇨🇦 CA

Who might be able to join this trial: - People who have been diagnosed with breast or colon cancer that has not spread to other parts of the body - People aged between 40 and 70 years old - People who have already begun chemotherapy or immunotherapy and still have at least three treatment sessions remaining in their cu...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06914245 · KU Leuven Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇧🇪 BE

Who might be able to join this trial: - A person must give their voluntary written agreement to participate before any screening takes place (or a legally authorised representative may do so on their behalf). - People who are at least 18 years old at the time of signing the consent form. - People who are able to read,...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06922383 · Isofol Medical AB Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 November 2028
🇩🇪 DE

**Who might be able to join this trial:** - People who have signed a consent form and are able to follow the study requirements - People with a laboratory-confirmed diagnosis of colorectal cancer (a specific type called adenocarcinoma) that has spread to other parts of the body, and who are being considered for first-...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06923150 · Qufora A/S Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇫🇷 FR

**Who might be able to join this trial:** - Adults aged 18 or older - People who have had surgery for rectal cancer called a low anterior resection (a procedure that removes part of the rectum while keeping the bowel connected) - People who are between 3 and 18 months after their bowel surgery, or between 3 and 18 mon...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06929013 · Hospices Civils de Lyon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 June 2026
🇫🇷 FR

**Who might be able to join this trial:** - Adults aged 18 or older, of any gender. - People who weigh at least 55 kg at the time of joining. - People who are willing and able to sign a consent form. - **Group 1:** People who have colorectal cancer that has spread to the lining of the abdomen (peritoneal metastases),...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06930586 · The First Affiliated Hospital of Zhengzhou University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older who have been diagnosed with rectal cancer, whether male or female **Who may not be able to join:** - No specific exclusion criteria were listed in the provided information (confirm with trial site) **Important:** Always verify eligibility with the t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06935708 · Meri Mirceta Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 October 2026
🇭🇷 HR

**Who might be able to join this trial:** - People aged 18 to 80 years who have colorectal cancer and are having laparoscopic (keyhole) abdominal surgery - People rated as ASA Class I, II, or III (a standard measure used by anaesthetists to describe overall health before surgery) (confirm with trial site) - People with...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06936774 · University Hospital, Basel, Switzerland Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 May 2028
🇨🇭 CH

Who might be able to join this trial: - Adults aged 18 years or older - People who have rectal cancer in the middle or lower part of the rectum (stages I to IV) and have had a specific type of bowel surgery (called LAR with TME) along with a temporary stoma (an opening in the abdomen to divert waste while the bowel hea...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06938971 · Rigshospitalet, Denmark Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
🇩🇰 DK

Who might be able to join this trial: - Adults aged 18 or older who are scheduled to start their first round of chemotherapy for colorectal cancer that has spread to other parts of the body. Who may not be able to join: - People who are pregnant. - People whose life expectancy is estimated to be less than 6 months. -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06940388 · brenner baruch Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 1 August 2029
🇩🇪 DE🇮🇱 IL

**Who might be able to join this trial:** - You have been diagnosed with rectal cancer (confirmed by a tissue sample) that has not come back after previous treatment, and the tumor is located within 12 cm of the opening of the back passage. - Your cancer is at a specific stage (T3-4 N0 or TX N+), as shown by MRI and P...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06940947 · Norwegian Department of Health and Social Affairs Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 September 2033
🇵🇱 PL

Who might be able to join this trial: - People who have been newly diagnosed with a type of colon cancer called adenocarcinoma, confirmed by a tissue sample (biopsy), where the cancer appears to have grown into the layer just below the surface lining and may be removable using a specialised endoscopic technique called...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06943612 · Heidelberg University Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 March 2026
🇩🇪 DE🇨🇭 CH

Who might be able to join this trial: - People who have been diagnosed with a retroperitoneal sarcoma (a type of soft tissue cancer found in the back of the abdomen), confirmed through a tissue sample examination - People whose treatment involves surgical removal of both the sarcoma and part of the colon or rectum at t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06946745 · jianming xu Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years (any gender) who are willing and able to sign a consent form and follow the trial's visit schedule and procedures. - People with a laboratory-confirmed diagnosis of advanced colorectal cancer (cancer that has spread or cannot be removed by surgery)...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06949098 · Hebei Medical University Fourth Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2032
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years old or older - You are generally well and able to carry out daily activities with little or no limitation (confirm with trial site) - You have been diagnosed with rectal cancer confirmed by a tissue sample (biopsy) - Your tumor is located in the lower part of...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06949111 · Hebei Medical University Fourth Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 February 2027
🇨🇳 CN

**Who might be able to join this trial:** - Adults aged 18 or older, of any gender - People whose general health and ability to carry out daily activities meets a certain standard (rated 0 or 1 on a scale doctors use called the ECOG scale, meaning fully active or able to do light activity) - People who have been confi...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06949982 · Sergey Orlov, MD Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 April 2027
🇷🇺 RU

**Who might be able to join this trial:** - Adults aged 18 or older - People who are well enough to carry out daily activities with little to no limitation (assessed using a standard scale called ECOG, scores 0–1) - People who have been diagnosed with colorectal cancer (bowel cancer) that has spread to other parts of...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06951503 · Akeso Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 13 January 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have given their written consent to participate - People aged 18 to 75 years old - People who are generally well enough to carry out light activity and care for themselves (a doctor assesses this using a standard scale called ECOG, with a score of 0 or 1) - People...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06952101 · Fondazione del Piemonte per l'Oncologia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇮🇹 IT

Who might be able to join this trial: - People who are 18 years of age or older - People who are able to read and sign a consent form agreeing to take part in the trial - People who have a high-risk early-stage rectal cancer (called pT1 rectal adenocarcinoma) that has already been removed by an endoscopic procedure - P...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06958926 · National Taiwan University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇹🇼 TW

Who might be able to join this trial: - People who are 18 years of age or older - People who have been diagnosed with colorectal cancer - People who are scheduled to have surgery to remove part or all of the colon or rectum, either to fully remove the cancer or to relieve symptoms, whether performed through small incis...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06959550 · M.D. Anderson Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2028
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older who are able to give signed consent to participate. - People who have been confirmed (through a tissue or cell sample) to have advanced or metastatic cancer of the colon or rectum (a type called adenocarcinoma). - People whose cancer has been tested f...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06964438 · University of Nottingham Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2027
🇬🇧 GB

**Who might be able to join this trial:** - Adults aged 18 or older at the time their diagnosis was discussed by a specialist team (called a multi-disciplinary team, or MDT) - People diagnosed with colorectal cancer, gastric (stomach) cancer, or a non-invasive growth in the bowel or stomach — either confirmed by tissu...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06965335 · Niguarda Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇮🇹 IT

Who might be able to join this trial: - People who have been diagnosed with colorectal cancer, either between the ages of 18 and 40, or diagnosed for the first time after the age of 60 - People who are able to sign a consent form agreeing to take part in the study - People for whom stored tumour tissue samples (preserv...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06979908 · The First Hospital of Jilin University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 22 July 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have given written consent and are able to follow the study requirements. - People aged 18 to 75 years old. - People who have been diagnosed with colorectal cancer (a type of bowel cancer called adenocarcinoma), confirmed by a tissue sample test. - People whose ca...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06980532 · Liu Huang Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who have been fully informed about the study and have agreed to take part by signing a consent form - Adults aged 18 or older - People who have been diagnosed with colorectal cancer that has spread and cannot be removed by surgery, and whose tumour has been confirmed...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06983639 · Sorlandet Hospital HF Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2040
🇳🇴 NO

**Who might be able to join this trial:** - People who had a high-quality colonoscopy where the doctor was able to reach the full length of the bowel and the bowel was well-cleaned beforehand - People who had at least one advanced polyp (a type of growth in the bowel) removed during that colonoscopy - People whose bowe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06992258 · Criterium, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are willing and able to sign and date a consent form. - People who are able to follow all study procedures and remain available for the full duration of the trial, as judged by the study doctor. - People aged 18 or older. - People who are generally well enough to...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06992648 · Second Affiliated Hospital, School of Medicine, Zhejiang University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have signed a consent form before any study procedures begin - Adults aged 18 or older - People with a confirmed diagnosis (from a tissue sample) of colon or rectal cancer that cannot be surgically removed, specifically the type called adenocarcinoma - People whos...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06995924 · Fred Hutchinson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2027
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older - People who have had surgery to remove Stage I, II, or III colorectal cancer, and are within 3 months of that surgery - People who are receiving care at one of the clinics taking part in this trial - People who are able to understand and complete surv...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06998745 · Sixth Affiliated Hospital, Sun Yat-sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with colorectal cancer (cancer of the colon or rectum) confirmed by a laboratory test, and who have also developed a blood clot (either noticed through symptoms or found by chance during testing), and who have been given blood-thinning medicatio...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07003022 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 80 years who have signed a consent form before enrolling - People diagnosed with advanced colorectal cancer that has a specific genetic feature called dMMR or MSI-H, confirmed through tissue or cell testing combined with imaging scans - People with a genera...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07005453 · Erasmus Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2026
🇳🇱 NL

**Who might be able to join this trial:** - You are between 55 and 80 years old - You are already scheduled to have a bowel cancer screening test (called a FIT test) or a follow-up colonoscopy - During your colonoscopy, the doctor finds one or more polyps (small growths in the bowel) that are no larger than 25 mm **Wh...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07012954 · Sun Yat-sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with colorectal cancer (a type of bowel cancer) confirmed by a laboratory tissue test, specifically a type called adenocarcinoma - People whose tumour was originally tested and found to have no RAS or BRAF gene mutations (called "wild-type") -...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07023289 · AbbVie Phase 2 · 8 countries Recruiting
Recruiting Phase 2 Est. completion 1 November 2029
🇧🇪 BE🇩🇰 DK🇮🇹 IT🇯🇵 JP🇰🇷 KR🇪🇸 ES🇹🇼 TW🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with cancer of the colon or rectum, confirmed through laboratory testing of a tissue or cell sample. - People who have surgical tumour tissue available that can be used to create a personalised cancer DNA tracking test called Signatera. - People who...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07035002 · Ruijin Hospital Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2025
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with advanced colorectal cancer, confirmed by a lab test on tissue or cell samples, and who are no longer able to receive standard treatments. - People who are willing to have surgery or a biopsy to collect tumor tissue, which will be used to prepar...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07035886 · Takeda Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2029
🇰🇷 KR

Who might be able to join this trial: - People aged 18 years or older. - People who are starting or will be treated with Fruzaqla in line with the approved guidelines in South Korea. - People who give their voluntary consent to take part in the study. Who may not be able to join: - People for whom Fruzaqla is listed a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07044921 · Chinese PLA General Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 July 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have agreed to take part and have signed a consent form, and who are willing and able to attend scheduled visits and follow the study plan - People aged 18 years or older, of any gender - People whose colorectal cancer has been confirmed by a pathology test and is...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07046585 · Natera, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 July 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are aged 40 or older at the time of signing the consent form - People who are already planning to have a routine colonoscopy as part of their normal medical care - People who are able to have blood drawn through a needle in a vein - People who are able to provide b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07047482 · Sohag University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 21 March 2026
🇪🇬 EG

Who might be able to join this trial: - Tissue samples taken from people who have been diagnosed with colorectal cancer (cancer of the colon or rectum) - Tissue samples that contain enough material to be tested and analysed - Samples that are accompanied by enough medical background information about the patient they c...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07050394 · Shanghai Changzheng Hospital Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 June 2028
🇨🇳 CN

Who might be able to join this trial: - Adults aged 18 or older, of any gender - People who have been diagnosed with colorectal cancer confirmed by a tissue or cell test - People whose colorectal cancer cannot be removed by surgery and has either spread locally or to other parts of the body - People whose cancer is no...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07056374 · Amsterdam UMC, location VUmc Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇳🇱 NL

**Who might be able to join this trial:** - People who have a biopsy-confirmed cancer of the sigmoid colon or upper rectum (at a specific early-to-moderate stage, without spread to distant parts of the body), where a surgical procedure called an anterior resection is the recommended treatment. - People who have a pre-...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07069556 · Geneoscopy, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2028
🇺🇸 US

**Who might be able to join this trial:** - People who are male or female and aged 45 or older (people aged 18–44 may also be enrolled but would not be included in the main results analysis) - People who are able to understand the study procedures and are willing to give their consent to take part, including signing a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07071987 · Northern Jiangsu People's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2027
🇨🇳 CN

Who might be able to join this trial: - People between 18 and 80 years of age - People who have been diagnosed with stage I, II, or III colorectal cancer - People who are scheduled for planned (non-emergency) keyhole surgery to remove part of the colon or rectum - People whose overall health before surgery has been rat...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07079462 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years of age or older. - You have been diagnosed with colorectal cancer that has spread to the lining of the abdomen (peritoneum), confirmed by a tissue or fluid sample test. - Your cancer got worse after receiving standard first-line treatment, and you have not p...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07079631 · BioNTech SE Phase 2 · 5 countries Recruiting
Recruiting Phase 2 Est. completion 1 December 2030
🇩🇪 DE🇯🇵 JP🇪🇸 ES🇬🇧 GB🇺🇸 US

Who might be able to join this trial: - People who have colorectal cancer (cancer of the colon or rectum) that cannot be removed by surgery, confirmed by a tissue test to be a specific type called adenocarcinoma. - People whose cancer has been tested and confirmed to be a type called non-MSI-H or pMMR (a specific genet...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07085169 · Ruijin Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged over 60 years old, both men and women - People who have been diagnosed with bowel cancer (colon or rectal cancer) confirmed by a tissue test (biopsy) - People whose cancer has spread or cannot be removed by surgery, and who have already tried two or more chemother...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07086833 · Purdue University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged between 45 and 75 years old - People who are up to date with bowel cancer screening (colonoscopy) and have been found to have a higher risk of bowel cancer — specifically, those who have had 3 or more growths called adenomatous polyps, or at least one polyp larger...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07087561 · Xiaoqin Luo Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 October 2029
🇨🇳 CN

Who might be able to join this trial: - People who are 18 years of age or older - People who have a confirmed diagnosis of colon or rectal cancer (confirmed through laboratory or tissue testing) - People whose cancer is classified as stage IIa, IIb, or IIIa - People who are mentally alert and able to communicate - Peop...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07090291 · Zhejiang University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2035
🇨🇳 CN

Who might be able to join this trial: - People who are between 45 and 74 years old - People who are in good general health, have a normal mental state, and are willing to sign a consent form agreeing to take part Who may not be able to join: - People who have a personal history of colorectal (bowel) cancer or pre-canc...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07095439 · Ain Shams University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2026
🇪🇬 EG

**Who might be able to join this trial:** - You are between 18 and 70 years old - You have been confirmed by a laboratory test to have a specific type of rectal cancer (adenocarcinoma) located in the lower or middle part of the rectum, within 16 cm of the anal opening - Your cancer has been classified as Stage II or St...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07104604 · Affiliated Cancer Hospital of Shantou University Medical College Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 March 2027
🇨🇳 CN

Who might be able to join this trial: - People aged between 18 and 75 years old, of any gender - People who are well enough to carry out daily activities with little or no limitation (based on a standard fitness scale used by doctors, scored 0 or 1) - People who have been confirmed through a biopsy to have a specific t...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07106034 · Shanghai Pudong Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 July 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years old at the time of signing the consent form, of any gender - People who have been diagnosed with a specific type of colorectal or rectal cancer (called MSS/pMMR) confirmed by tissue testing, whose cancer has gotten worse after receiving a standard...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07106892 · Shanghai Henlius Biotech Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who fully understand what the study involves, including possible side effects, and have signed a consent form agreeing to take part and follow the study requirements - People aged 18 to 75 years at the time of signing the consent form, of any sex - People who have bee...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07107230 · Janssen Research & Development, LLC Phase 1 · 3 countries Recruiting
Recruiting Phase 1 Est. completion 18 November 2027
🇰🇷 KR🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** - People who have previously been diagnosed with a confirmed form of one of these cancers that cannot be surgically removed, has spread locally, or has spread to other parts of the body: non-small cell lung cancer, colorectal cancer, or head and neck squamous cell carcinoma -...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07112690 · Emory University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with localised anal cancer or perianal skin cancer (cancer of the skin around the anus), and who have either started or are about to start chemotherapy and radiation treatment for their cancer - People who are regularly reporting pain levels of 5 or...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07113275 · Tao Zhang Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 January 2028
🇨🇳 CN

Who might be able to join this trial: - The patient, or a family member on their behalf, is willing to agree to take part and sign a consent form - Aged between 18 and 75 years old, of any gender - Diagnosed with locally advanced rectal cancer (a specific type called adenocarcinoma), confirmed by a tissue sample - Tumo...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07130903 · Barbara Ann Karmanos Cancer Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 17 April 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with colorectal cancer that has spread to other parts of the body, confirmed by laboratory testing of tissue or cell samples, with previous test results on file for certain genetic and protein markers (RAS, BRAF, MSI/MMR, and HER2). - People wh...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07140679 · Emory University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 September 2029
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with stage IIB, IIC, or III colon cancer that has a specific genetic feature called "mismatch repair deficiency" (dMMR) or "microsatellite instability-high" (MSI-H), confirmed by laboratory testing - Your colon cancer was completely surgically removed...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07143487 · Alliance for Clinical Trials in Oncology Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 5 November 2029
🇺🇸 US

Who might be able to join this trial: **For the main participants (called "probands") — Step 1:** - Adults aged 18 or older who have been newly diagnosed with primary colorectal cancer (colon or rectal cancer) within the last 3 months, at any stage from Stage I to Stage IV - People whose cancer has been confirmed by l...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07147231 · National Cancer Institute (NCI) Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 September 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with colorectal cancer (a type of cancer starting in the colon or rectum) that has spread or cannot be surgically removed, and for which standard treatments are no longer working or do not exist. - People whose cancer can be measured on scans, acco...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07148297 · Epiliquid Holding, Inc Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2025
🇦🇷 AR

Who might be able to join this trial: - People who are scheduled to have a colonoscopy or colorectal surgery - People who are willing and able to give their informed consent to participate - People who are able to provide a blood and/or tissue sample before their treatment or surgery Who may not be able to join: - Peo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07153016 · Masonic Cancer Center, University of Minnesota Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

Who might be able to join this trial: **For patients with colorectal cancer:** - People who have been diagnosed with advanced colorectal cancer (Stage III or Stage IV) within the past 3 months - People who have started, or are planning to start, systemic cancer treatment (treatment that works throughout the whole body...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07154173 · Sixth Affiliated Hospital, Sun Yat-sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

Who might be able to join this trial: - Adults between 18 and 75 years old - People who have been diagnosed with colorectal cancer confirmed by laboratory testing of tissue samples - People whose cancer has been clearly staged through scans or tissue testing, either with spread to distant parts of the body (stage M1) o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07163403 · Fundacion Clinic per a la Recerca Biomédica Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 20 September 2028
🇪🇸 ES

**Who might be able to join this trial:** - You carry a genetic change (variant) in one of the following DNA repair genes: MLH1, MSH2, or MSH6, which is known or likely to increase cancer risk. - You have no current or past history of invasive cancer. - Your colon can be reached and examined using a standard camera pr...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07168876 · Epiliquid Holding, Inc Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇦🇷 AR

Who might be able to join this trial: - Men and women between the ages of 45 and 75 years old - People whose treating doctor has recommended a colonoscopy for colorectal cancer screening Who may not be able to join: - People who have a parent, sibling, or child who has had colorectal cancer - People who have an inflam...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07189312 · Universidad de Granada Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 February 2026
🇪🇸 ES

Who might be able to join this trial: - People who have been diagnosed with colorectal cancer (cancer of the colon or rectum) - People whose cancer treatment plan includes surgery - People whose cancer does not show a certain genetic marker called microsatellite instability (confirm with trial site) - People who do not...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07192055 · Medical College of Wisconsin Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2028
🇺🇸 US

**Who might be able to join this trial:** - People who are HIV-positive and aged 35 or older, or people who are HIV-negative and aged 45 or older - People who are cisgender or transgender gay, bisexual, or other men who have sex with men, or transgender women who have sex with men - People who currently live in the Chi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07194616 · University Hospital Ostrava Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 March 2028
🇨🇿 CZ

Who might be able to join this trial: - Adults aged 18 or older - People who have been diagnosed with rectal cancer (a specific type called adenocarcinoma), confirmed through a tissue sample, where the tumor is located within 12 cm of the opening of the back passage - People whose cancer is at stage II or stage III, me...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07198581 · Incheon St.Mary's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2026
🇰🇷 KR

Who might be able to join this trial: - Adults aged 18 or older who have been diagnosed with breast cancer or colorectal cancer, confirmed through a tissue or biopsy test - People who are planned to receive at least 3 months of chemotherapy treatment - People whose general health and ability to carry out daily activiti...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07199127 · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 August 2025
🇮🇹 IT

Who might be able to join this trial: - People who have been diagnosed with Familial Adenomatous Polyposis (FAP) — a hereditary condition causing many polyps — confirmed through genetic testing - People who have had two or more camera examinations of the upper digestive tract (a procedure that looks inside the stomach...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07201519 · Michael J Cavnar, MD Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 February 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have colorectal cancer (a specific type called adenocarcinoma) that has spread to the liver, where the liver tumours are either unable to be surgically removed (Group A) or can be completely surgically removed (Group B), and where cancer has not clearly spread to...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07208786 · Nanchong Central Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 October 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with colorectal cancer through laboratory testing and are planned to have surgery to remove part of the colon or rectum. - People between 18 and 85 years of age who have been assessed by an anaesthetist as being in generally acceptable health f...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07209787 · Beijing Chao Yang Hospital Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 30 June 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 85 or younger, of any gender - People who have been diagnosed with rectal cancer where the tumour is located in the middle or lower part of the rectum (within 10 cm of the anal opening) and where a specific surgical joining technique using a circular stapling dev...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07216560 · Mabwell (Shanghai) Bioscience Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2027
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older - People with a good general level of physical functioning (rated 0 or 1 on a standard performance scale used by doctors) - People with a life expectancy of at least 3 months - People with advanced or metastatic (spread to other parts of the body) gastroin...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07221058 · Fox Chase Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 November 2028
🇺🇸 US

**Who might be able to join this trial:** - A tissue sample (biopsy) must have confirmed a diagnosis of rectal adenocarcinoma (a specific type of rectal cancer). - The cancer must be at a specific stage — classified as T2-3, N0-1, M0 — meaning it has grown into but not beyond the rectal wall, with no or limited nearby...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07224841 · City of Hope Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 18 June 2028
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with metastatic colorectal cancer (cancer that started in the colon or rectum and has spread to other parts of the body), confirmed by laboratory testing of tissue samples. - People who have already received treatment with a therapy targeting EGFR (...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07227636 · Memorial Sloan Kettering Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2030
🇺🇸 US

**Who might be able to join this trial:** - The person joining (or their legal representative) must be willing and able to give written consent to participate. - A diagnosis of colorectal cancer must have been confirmed through laboratory testing of tissue samples. - People aged 18 or older at the time of signing the...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07228832 · Summit Therapeutics Phase 3 · 12 countries Recruiting
Recruiting Phase 3 Est. completion 31 May 2028
🇧🇪 BE🇨🇦 CA🇨🇿 CZ🇫🇷 FR🇩🇪 DE🇮🇹 IT🇯🇵 JP🇵🇱 PL +4 more

**Who might be able to join this trial:** - People whose cancer has spread (metastatic colorectal cancer) confirmed by laboratory testing of a tissue or cell sample - People who are generally well enough to carry out daily activities with little or no limitation (this is measured using a standard scoring system called...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07235865 · Niguarda Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2025
🇮🇹 IT

Who might be able to join this trial: - People who are 12 years of age or older - People who have a suspected or confirmed growth or lump in or around the heart, identified through standard medical tests such as scans, imaging, or tissue testing Who may not be able to join: - People who are unable to fully understand...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07237438 · Grigore T. Popa University of Medicine and Pharmacy Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2026
🇷🇴 RO

Who might be able to join this trial: - Adults who have been diagnosed with colorectal cancer and are scheduled to have open colorectal surgery at the Regional Institute of Oncology in Iași, Romania Who may not be able to join: - People who are unable to give their own informed consent to participate - People who have...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07239466 · Tao Zhang Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - The patient, or their family member on their behalf, must agree to take part and sign a consent form - Adults aged 18 to 75 years, of any gender - People who have been confirmed through a tissue biopsy to have locally advanced rectal cancer (a specific type called adenocarci...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07247396 · Second Affiliated Hospital, School of Medicine, Zhejiang University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 May 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years old at the time of signing the consent form - People who have been diagnosed with colorectal cancer that has spread to the lining of the abdomen (called peritoneal metastases), confirmed by laboratory testing - People whose cancer has stopped respo...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07249333 · Oncology Institute of Vojvodina Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇷🇸 RS

Who might be able to join this trial: - You must be an adult aged 18 or over - You must have been assessed as being relatively fit and active, with a Clinical Frailty Scale score of 2, 3, or 4 (this is a score given by a doctor to describe how independent and active a person is — confirm with trial site) - You must be...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07253896 · Second Affiliated Hospital, School of Medicine, Zhejiang University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 3 January 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing and able to sign a written consent form agreeing to take part. - People aged 18 to 75 years old, of any gender. - People who are generally fit and able to carry out everyday activities, as measured by a standard health performance score of 0 or 1 (conf...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07254910 · University of Oklahoma Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇺🇸 US

Who might be able to join this trial: - You are between 45 and 75 years old - You live within the IHS Clinton Service Unit catchment area (confirm with trial site if you are unsure whether your location qualifies) - You are comfortable speaking English and can read at a 6th grade level or above - You identify as Americ...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07255729 · City of Hope Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 18 June 2028
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with colon cancer (any stage from I to IV) confirmed through laboratory testing of tissue samples - People who have had surgery aimed at fully removing the cancer, with or without additional treatments before or after the operation - People who have...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07257653 · Zhejiang University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to take part voluntarily and agree to follow the study requirements by signing a consent form - People aged 10 to 80 years old who are generally well enough to carry out normal daily activities with little or no limitation; people aged 80 to 85 may als...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07259590 · Genfleet Therapeutics (Shanghai) Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to take part voluntarily and sign a consent form. - People aged 18 or older for Treatment Arm A, or between 18 and 75 years old for Treatment Arm B. - People who have been diagnosed (through tissue or cell testing) with a locally advanced, inoperable, o...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07260526 · West China Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 80 years old, of any sex - People who have been diagnosed with rectal cancer (a specific type called adenocarcinoma), confirmed by a biopsy, and whose tumour has been tested and shown to have a particular molecular profile called pMMR/MSS - People...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07262840 · China Medical University, China Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 February 2026
🇨🇳 CN

Who might be able to join this trial: - People who are considered high-risk for colorectal (bowel) cancer based on guidelines set by a major US cancer organisation (the NCCN) and relevant Chinese medical expert guidelines on colorectal cancer - People aged 18 years or older - People who can communicate and understand s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07264556 · Fudan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2025
🇨🇳 CN

Who might be able to join this trial: - People between 18 and 80 years old - People rated as generally healthy to moderately unwell before surgery, based on a standard medical assessment used by anaesthetists (known as ASA physical status I–III) - People scheduled for planned colorectal cancer surgery performed under g...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07272772 · Turku University Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 October 2026
🇫🇮 FI

**Who might be able to join this trial:** - You have been diagnosed with colon cancer and scans suggest it may have spread to nearby lymph nodes in the abdomen before your main surgery - You have colon cancer that has spread to other parts of the body, but doctors believe it could potentially be treated or removed - Yo...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07276529 · GI Windows, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇺🇸 US

**Who might be able to join this trial:** - You are 22 years of age or older at the time of screening - You are scheduled for a specific type of large bowel (colon) removal surgery, and your doctors have confirmed you are healthy enough to have it - You are able to read, understand, and sign a consent form for the stu...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07276932 · Second Affiliated Hospital, School of Medicine, Zhejiang University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇨🇳 CN

Who might be able to join this trial: - People who have been clinically diagnosed with colorectal cancer - People who have received chemotherapy after surgery for their cancer - People who have been diagnosed with a specific pattern involving low energy (qi deficiency) and constipation (confirm with trial site) - Peopl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07279077 · Sixth Affiliated Hospital, Sun Yat-sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 25 November 2030
🇨🇳 CN

**Who might be able to join this trial:** - People who have given their written agreement to take part voluntarily - People aged 18 to 75 years old at the time of joining - People who are generally well enough to carry out daily activities with little or no limitation (as measured by a standard medical fitness scale c...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07283367 · Hansoh BioMedical R&D Company Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2029
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years old or older (male or female) - You have been officially diagnosed with advanced colorectal cancer confirmed by a laboratory test - You have at least one measurable area of cancer in your body that is not in the brain or spinal cord - Your cancer has been tes...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07283575 · Fudan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 October 2028
🇨🇳 CN

**Who might be able to join this trial:** - Adults aged 18 or older, of any gender - People who have been diagnosed with colorectal cancer (confirmed by a tissue sample) that has come back or spread to other parts of the body - People whose doctors consider them suitable to receive radiation therapy combined with stand...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07291180 · Yale University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with cancer that has spread to the lining of the abdomen (peritoneal metastases), confirmed by a tissue biopsy, from one of these sources: appendix cancer (moderate to poorly aggressive, or signet ring cell type), colorectal cancer, or suspecte...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07296237 · Aarhus University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇩🇰 DK

Who might be able to join this trial: - Women who are 18 years of age or older - People who have been diagnosed with anal cancer - People who received chemoradiotherapy (a combination of chemotherapy and radiation treatment) with the goal of curing the cancer - People who finished their radiation treatment between 6 an...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07309289 · Shanghai Zhongshan Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 March 2029
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older - People who have been diagnosed through laboratory testing with colorectal cancer (a type of bowel cancer) that has spread to other parts of the body and cannot be removed by surgery - People whose advanced, spread cancer has not yet been treated wit...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07328087 · Biogenea Pharmaceuticals Ltd. Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 2 December 2030
🇬🇷 GR

**Who might be able to join this trial:** - People who have been diagnosed with colon or rectal cancer confirmed by a tissue biopsy, with pathology records available for review. - People whose cancer has been classified as stage III (meaning it has spread to nearby lymph nodes but not to distant parts of the body), ba...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07333053 · Quanda Liu Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older - People who have been diagnosed with colorectal cancer confirmed through a CT or MRI scan and a tissue sample taken during a colonoscopy - People whose cancer cannot be treated with surgery, either because of their overall health or because of where t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07337590 · Exero Medical Ltd. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇺🇸 US

**Who might be able to join this trial:** *Interventional group (active participants):* - Adults aged 21 or older who are scheduled for a planned bowel surgery called a low anterior resection, due to colorectal cancer - People whose surgical join (anastomosis) in the bowel is expected to be made within 10 cm of the op...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07337876 · University Hospital Tuebingen Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2029
🇩🇪 DE

**Who might be able to join this trial:** - People who have been diagnosed with rectal cancer that has been confirmed by a tissue sample (biopsy), where the tumour is located in a specific part of the rectum (between 0 and 12 cm from the anal opening) - People whose cancer has been staged by MRI scan as early-to-moder...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07339904 · University Hospital, Antwerp Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2029
🇧🇪 BE

Who might be able to join this trial: - You are 18 years old or older. - You have been diagnosed with rectal cancer that has been reviewed by a specialist team, and the plan is to perform surgery that preserves the muscle that controls bowel movements (with or without additional treatment before surgery). Who may not...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07345676 · Yale University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are adult patients at Cornell Scott Hill Health Center, meaning they have a primary care doctor there or have had more than one adult medicine visit at that clinic in the past year. - People who have been given an order for a bowel cancer screening test (such as a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07347951 · First Affiliated Hospital of Wenzhou Medical University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - You want to keep your anus (avoid a permanent colostomy bag) and are willing to complete the full course of pre-surgery treatment offered in this trial. - You are between 18 and 75 years old (any gender). - Scans and camera tests have shown your rectal tumor is within 10 cm o...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07349043 · Second Affiliated Hospital, School of Medicine, Zhejiang University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 October 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with colorectal cancer that has spread to the lining of the abdomen (peritoneum), confirmed by a tissue test, and has not spread to any other parts of the body - People aged 18 to 75 years old (any gender) - People whose general physical fitnes...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07351071 · Medtronic - MITG Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

Who might be able to join this trial: - People who are able to understand the study and are willing to sign a consent form agreeing to take part - People who are scheduled for a planned (non-emergency) surgical procedure on the left side of the colon or rectum, where the surgeon will reconnect the bowel using a specifi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07352280 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇨🇳 CN

Who might be able to join this trial: - Adults aged 18 or older who are generally well enough to carry out daily activities (rated on a standard medical scale as 0, 1, or 2 out of 4) - People with a confirmed diagnosis of stage II or stage III colorectal cancer (a type of bowel cancer) based on laboratory testing of ti...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07353632 · Esbjerg Hospital - University Hospital of Southern Denmark Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2027
🇩🇰 DK

Who might be able to join this trial: - Adults who are having a colonoscopy (a camera examination of the bowel) as part of Denmark's national bowel cancer screening program - People who have given written agreement to take part in the trial Who may not be able to join: - People who are unable to understand or communic...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07359989 · Second Affiliated Hospital, School of Medicine, Zhejiang University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have chosen to take part voluntarily, are willing to sign a consent form, and are able to attend follow-up appointments - People aged 18 to 80 years (inclusive), of any gender - People who have been diagnosed with locally advanced rectal cancer (a specific type ca...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07361614 · NYU Langone Health Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2027
🇺🇸 US

Who might be able to join this trial: - People aged between 45 and 75 years old - People who have not had a stool test for bowel cancer within the past year - People who have not had a colonoscopy in the past 10 years, and have not had a sigmoidoscopy or CT scan of the colon in the past 5 years - People who can underst...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07369531 · The First Hospital of Jilin University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2031
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years who have been diagnosed with rectal cancer confirmed by a tissue biopsy as a type called adenocarcinoma - People whose scans (CT of the abdomen and chest, or PET-CT) showed no signs of cancer that has spread to other parts of the body before surger...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07369830 · Huashan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 March 2029
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 75 years - People who have been diagnosed with rectal cancer very close to the anal sphincter muscles, where a type of surgery called Intersphincteric Resection (ISR) is the recommended surgical approach - People who have had a temporary ileostomy (...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07371273 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 7 January 2029
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with rectal cancer confirmed through physical examination, a camera examination of the bowel (colonoscopy), and a tissue sample (biopsy). - People whose tumour is located very close to the lower end of the rectum, specifically between 1.5 and 2.0 cm...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07372300 · Shih-Kai Hung Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2027
🇹🇼 TW

**Who might be able to join this trial:** - People aged 20 years or older - People of any gender - People whose initial diagnosis (confirmed by tissue sample) is a type of rectal cancer called adenocarcinoma - People whose doctors expect them to live at least 6 months - People whose rectal cancer is at a certain stage...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07388953 · Faculdade de Ciências Médicas de Minas Gerais Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 5 December 2026
🇧🇷 BR

Who might be able to join this trial: - People who are scheduled for a planned (non-emergency) keyhole surgery to remove part of the left side of the large bowel or rectum - People considered to be in generally good or only mildly affected overall health, as assessed by their medical team - People who are able to under...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07389265 · University of Campania Luigi Vanvitelli Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 1 October 2030
🇮🇹 IT🇪🇸 ES

**Who might be able to join this trial:** - People who have been diagnosed with colorectal cancer (bowel cancer) that has been confirmed by a tissue biopsy and has spread to other parts of the body. - People whose cancer responded well to a first round of treatment that included a type of drug called an anti-EGFR ther...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07393048 · Beijing Friendship Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - You have agreed in writing to take part in the study voluntarily - You are between 18 and 75 years old (any sex) - Your doctors have confirmed through a tissue sample (biopsy) that you have rectal cancer of a specific type called adenocarcinoma - Your cancer has been assesse...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07397338 · Revolution Medicines, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2029
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older who have given their informed consent to participate. - People with a performance status rating of 0 or 1 on the ECOG scale, meaning they are fully active or have only minor restrictions on physical activity. - People who have a confirmed locally adva...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07405476 · Emory University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 18 December 2028
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with colon and/or rectal cancer (confirmed by a lab test) and your doctors are planning to treat it with the goal of curing it at Emory University's Winship Cancer Institute or a partner center - Your tumor tests positive for a protein called HER2, co...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07407465 · Gruppo Oncologico del Nord-Ovest Phase 2 · 4 countries Recruiting
Recruiting Phase 2 Est. completion 20 October 2027
🇫🇷 FR🇩🇪 DE🇮🇹 IT🇪🇸 ES

**Who might be able to join this trial:** - People aged 18 or older at the time of signing the consent form - People who are willing and able to follow all study procedures and attend appointments at the participating treatment centre - People whose cancer has been confirmed by laboratory testing as adenocarcinoma of...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07416552 · Hoffmann-La Roche Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 12 February 2034
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with bowel cancer (starting in the colon or rectum) that has spread to other parts of the body (Stage IV), confirmed by a tissue test - People whose cancer has been tested and found to be a specific type called MSS and/or "proficient mismatch r...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07417358 · Umeå University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2028
🇸🇪 SE

**Who might be able to join this trial:** - People aged 18 or older - People who are scheduled (not emergency) for a planned left-sided bowel removal surgery that includes joining the bowel back together (anastomosis), such as a left hemicolectomy, sigmoid resection, or partial mesorectal excision (PME) - People having...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07422974 · Osijek University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇭🇷 HR

Who might be able to join this trial: - Adults aged 18 years or older who have been diagnosed with colorectal cancer confirmed by a laboratory tissue test - People who are scheduled to have surgery for colorectal cancer, either using a keyhole (laparoscopic) approach or open surgery - People who are able to understand...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07425054 · Jennifer Dorth Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2029
🇺🇸 US

**Who might be able to join this trial:** - People who have been confirmed by a laboratory test (biopsy) to have squamous cell carcinoma of the anal canal or anal margin at certain stages, including some who have had the main tumor surgically removed but still have cancer in nearby lymph nodes or remaining disease. -...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07427901 · Institute of Oncology Ljubljana Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2024
🇸🇮 SI

Who might be able to join this trial: - People who have been diagnosed with colorectal cancer (cancer of the colon or rectum) - People between the ages of 25 and 65 years old - People whose first cancer treatment took place at the Institute of Oncology Ljubljana - People who are currently able to work (confirm with tri...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07432399 · Institute of Oncology Ljubljana Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2027
🇸🇮 SI

**Who might be able to join this trial:** - Adults aged 18 years or older - People who have been diagnosed with colon cancer confirmed through a tissue sample (biopsy or similar test) - People who are already scheduled to have surgery to remove their colon cancer - People whose treating doctor determines they are suita...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07433673 · Columbia University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2028
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with a specific type of bile duct or gallbladder cancer called adenocarcinoma, confirmed by a tissue sample (biopsy). - People whose cancer cannot be surgically removed and has not spread to distant parts of the body, confirmed by a specialist radio...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07446322 · Oncolytics Biotech Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 August 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with colon or rectal cancer that has spread to other parts of the body, confirmed by a lab test on a tissue sample - Your cancer can be measured on a scan using standard medical guidelines - Surgery or radiation to cure your cancer is not an option for...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07448142 · Sun Yat-sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2027
🇨🇳 CN

Who might be able to join this trial: - People who have given written consent before any study procedures begin. - People aged 18 to 75 years at the time of joining the trial. - People whose rectal cancer has been confirmed by a tissue biopsy as a specific type called adenocarcinoma. - People whose tumor is located wit...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07450612 · San Raffaele University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 January 2031
🇮🇹 IT

Who might be able to join this trial: - People who had a colonoscopy done at the same time their blood sample was taken - People who went through the standard tests used to diagnose and stage their condition according to local medical guidelines, and who had at least one blood sample taken before starting any treatment...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07458529 · Seventh Medical Center of PLA General Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 5 May 2027
🇨🇳 CN

**Who might be able to join this trial:** - Adults aged 18 or older - People whose general health and ability to carry out daily activities falls within an acceptable range, as measured by a standard medical scale called ECOG (scores 0–2) - People who have been diagnosed with rectal cancer (a specific type called aden...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07463599 · HonorHealth Research Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2029
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with a specific type of colorectal cancer (adenocarcinoma) that has spread to other parts of the body, confirmed by a tissue or cell sample - Your cancer has been tested for certain genetic markers (RAS, BRAF, and MS...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07468630 · Daping Hospital and the Research Institute of Surgery of the Third Mil... Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to take part and have signed a consent form agreeing to participate. - You have been diagnosed with colon cancer (a specific type called adenocarcinoma) that has been confirmed by a tissue sample, and it is at stage cT3c or more advanced. - You are between 18...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07477522 · West China Hospital Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 June 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have given written consent before any study-related procedures begin. - People aged between 18 and 80 years old, male or female. - People who have been diagnosed with a solid tumour confirmed by a tissue biopsy. - People who have at least one tumour that can be me...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07494201 · Fondazione del Piemonte per l'Oncologia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2027
🇮🇹 IT

**Who might be able to join this trial:** - People who have been diagnosed with colon or rectal cancer, confirmed by a tissue sample taken during a camera examination of the bowel - People at any stage of cancer spread, including cases where the cancer has or has not spread to other parts of the body, as long as surge...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07501845 · Maastricht Radiation Oncology Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2034
🇳🇱 NL

Who might be able to join this trial: - Adults aged 18 years or older. - People who have been diagnosed with rectal cancer confirmed by a tissue sample, or where rectal cancer is strongly suspected based on medical imaging. - People whose treatment plan includes a specific radiation device called the MAASTRO HDR rectal...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07503756 · Shanghai Junshi Bioscience Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - Adults between 18 and 75 years old whose colorectal cancer has spread (metastatic) and has been confirmed by a laboratory test (biopsy) - People whose cancer has a specific genetic profile known as microsatellite stable (MSS) or mismatch repair proficient (pMMR) (confirm wit...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07504523 · Ying Yuan, MD Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - Adults between 18 and 70 years of age - People who have been diagnosed with advanced colorectal cancer, confirmed by both laboratory tissue testing and imaging scans, with at least one tumour that can be measured on a scan - People whose cancer has not responded to standard...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07505472 · The First Hospital of Jilin University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2029
🇨🇳 CN

**Who might be able to join this trial:** - The patient and their family are able to understand the study and are willing to sign a consent form agreeing to take part - Adults aged 18 to 75 years old, of any gender - A tissue sample (biopsy) has confirmed the person has rectal cancer of a specific type called tubular...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07506005 · Kepler University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇦🇹 AT

Who might be able to join this trial: - Adults aged 18 years or older - People who have had colorectal surgery where the bowel was rejoined using a specific stapling method called the double-stapling technique, including side-to-end or end-to-end connections - People whose surgical records clearly document which way th...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07506109 · Tianjin Medical University Cancer Institute and Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - You have agreed to take part by signing a consent form - You are 18 years of age or older - Your cancer has been confirmed by a lab test to be colorectal adenocarcinoma (a specific type of bowel cancer) - Your cancer has been tested and shown to have a specific genetic profil...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07512232 · Sun Yat-sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2028
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 75 years old - People who have been diagnosed with a specific type of rectal cancer (rectal adenocarcinoma) confirmed by laboratory testing - People whose rectal tumor is located in the middle to lower part of the rectum, within 10 cm of the anal op...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07523919 · Inonu University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 March 2028
Turkey (Türkiye)

Who might be able to join this trial: - People who are between 18 and 80 years old - People who are willing to take part in the study voluntarily Who may not be able to join: - People who have a condition affecting their muscles, bones, or joints that might stop them from completing the required tests - People who hav...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07529301 · Müşerref Ebru YALÇIN Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 August 2026
Turkey (Türkiye)

Who might be able to join this trial: - You are between 18 and 80 years old - You are willing to take part in the study by your own choice Who may not be able to join: - You decide you no longer want to take part in the study after joining - You have a condition affecting your muscles, bones, or joints that might stop...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07541924 · DONG WU Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 January 2026
🇨🇳 CN

Who might be able to join this trial: - Adults between 18 and 80 years old, or those with a life expectancy of more than 3 years - People who are scheduled to have a colonoscopy at Peking Union Medical College Hospital - People who have had a CT scan of the abdomen or pelvis within the last 5 years and have not had maj...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07542171 · Nanfang Hospital, Southern Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2028
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with early-stage colorectal cancer confirmed by a tissue sample (biopsy) - You have had your cancer removed using an endoscopic procedure (a procedure performed through a camera inserted into the bowel, without open s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07543744 · R-Pharm Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 15 May 2026
🇷🇺 RU

**Who might be able to join this trial:** - People who have signed and dated a consent form agreeing to take part in the study - People who have been confirmed by laboratory testing to have metastatic colorectal adenocarcinoma (a type of bowel cancer that has spread to other parts of the body), or who are willing to h...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07546565 · University Medical Center Ho Chi Minh City (UMC) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2027
🇻🇳 VN

Who might be able to join this trial: - People who have been diagnosed with colon cancer classified as stage I, II, or III (meaning the cancer has not spread to distant parts of the body) - People who are scheduled for a planned (non-emergency) surgical procedure to remove the right portion of the colon, performed usin...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07555678 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 75 years old - You have been diagnosed with squamous cell carcinoma (a specific type of cancer) of the anal canal or the skin area around the anus, confirmed by a pathology test - You are generally well enough to carry out daily activities with little...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07558083 · University Hospital, Antwerp Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2029
🇧🇪 BE

Who might be able to join this trial: - Adults aged 18 or older at the time they give their consent to participate - People whose overall health and ability to carry out daily activities falls within an acceptable range, as measured by a standard medical scale (called ECOG performance status 0–2, meaning fully active t...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07561060 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who are able to give written consent and are willing to follow the trial schedule and requirements - People aged 18 to 75 years old - People who have been diagnosed with rectal adenocarcinoma (a specific type of rectal cancer), confirmed through laboratory testing of...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07562490 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇨🇳 CN

Who might be able to join this trial: - Adults aged 18 or older, of any sex - People with an activity and health status score (called ECOG) rated 0, 1, or 2, meaning they are able to carry out at least some daily activities, with an expected survival of more than 3 months - People who have been diagnosed through labora...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07562503 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older, of any sex - People whose general health and ability to carry out daily activities falls within an acceptable range, as measured by a standard oncology scale (ECOG score of 0–2), with a life expectancy of more than 3 months - People who have been dia...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07562659 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older, of any sex - People whose general health and ability to carry out daily activities falls within an acceptable range on a standard medical scale (ECOG score of 0–2), with a life expectancy of more than 3 months - People who have been diagnosed through...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07566559 · Beijing Friendship Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇨🇳 CN

Who might be able to join this trial: - People who have been fully informed about the trial and have signed a written consent form - People who have been diagnosed with rectal adenocarcinoma (a specific type of rectal cancer) confirmed through a colonoscopy biopsy and pathology results - People whose cancer is classifi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07573371 · Aalborg University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇩🇰 DK

**Who might be able to join this trial:** **General requirements (all participants):** - People who can read and understand Danish - Adults aged over 18 years who are able to make their own legal decisions - People who study staff have assessed as able to understand the study, follow the procedures, attend hospital ap...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07579780 · Sixth Affiliated Hospital, Sun Yat-sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 18 December 2026
🇨🇳 CN

Who might be able to join this trial: - People who are able to give their informed consent to participate. - People who are scheduled to have planned (elective) keyhole surgery to remove colorectal cancer. - People whose overall physical health falls within a standard pre-surgery classification range of Class I to III...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07581912 · Zhejiang University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to take part voluntarily and agree to sign a consent form - People aged between 18 and 80 years old who are generally active and able to care for themselves (PS score 0–1) - People who have been confirmed by tissue testing to have colorectal adenocarci...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07589517 · Beijing Biotech Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 14 March 2027
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with colorectal cancer (a specific type called adenocarcinoma) that has spread or cannot be removed by surgery, and standard treatments have stopped working, caused intolerable side effects, or are not an option for you. - Your cancer can be measured o...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07594925 · Tianjin Medical University Cancer Institute and Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2029
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 75 years old (any gender) - You have been diagnosed with Stage II or Stage III rectal cancer, with no spread to distant parts of the body, as confirmed by MRI or internal ultrasound scan - Your tumor is located in the lower part of the rectum, no more...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07604909 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 10 September 2027
🇨🇳 CN

**Who might be able to join this trial:** - Adults aged 18 or older, of any gender - People who have been diagnosed with colorectal cancer that came back within 1 year after surgery (classified as stage IV), where the cancer has spread to other parts of the body that cannot be surgically removed, or where the person h...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07605611 · Tongji Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2027
🇨🇳 CN

**Who might be able to join this trial:** - Adults between 18 and 75 years old - People with early to mid-stage rectal cancer (stage I to III) who are planned to have a type of bowel surgery called a low anterior resection at a participating surgical centre - People whose tumour is located close enough to the lower end...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07608120 · Nanfang Hospital, Southern Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2027
🇨🇳 CN

**Who might be able to join this trial:** - Adults between 18 and 75 years of age who are already scheduled to have a planned (non-emergency) colonoscopy - People who have a standard medical reason for needing a colonoscopy - People who are able to understand and follow the bowel preparation instructions, including dri...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07611266 · Beijing Friendship Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 May 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with colorectal adenoma (a type of non-cancerous growth in the bowel) according to standard medical criteria, and who also meet certain criteria related to Traditional Chinese Medicine (TCM) body types or patterns (confirm with trial site for de...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07616297 · Claudia Schuurhuizen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2029
🇳🇱 NL

**Who might be able to join this trial:** - People who are 18 years of age or older - People whose general health and ability to carry out daily activities meets a certain minimum level, as assessed using a standard medical scale (confirm with trial site) - People who have been diagnosed with a specific type of rectal...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07618273 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 April 2027
🇺🇸 US

Who might be able to join this trial: - Adults between the ages of 18 and 44 years old - People who have concerns about their digestive or gut health - People who are able to speak and read English - People who are willing to track their symptoms over a four-week period as part of the study Who may not be able to join...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07628998 · Corporacion Parc Tauli Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇪🇸 ES

Who might be able to join this trial: - People aged between 50 and 69 years old, of any gender - People who live in the Vallès Occidental area - People who were invited to the Colorectal Cancer Screening Program but had not participated within 5 weeks of receiving that invitation Who may not be able to join: - People...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07644286 · Tao Zhang Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 25 January 2027
🇨🇳 CN

Who might be able to join this trial: - People who are able to give written consent and are willing to attend all required visits and follow the study procedures. - People aged 18 to 75 years old, of any gender. - People who have been diagnosed with colorectal cancer (confirmed by laboratory testing of tissue or cells)...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07646639 · The First Affiliated Hospital with Nanjing Medical University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - Adults between 18 and 70 years old (male or female) - People with a confirmed diagnosis of rectal cancer (a specific type called adenocarcinoma) where the tumour is located in the lower part of the rectum, within about 12 cm of the anal opening - People whose cancer has been...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07649057 · Memorial Sloan Kettering Cancer Center Not Applicable · 4 countries Recruiting
Recruiting Not Applicable Est. completion 11 June 2028
Ghana🇿🇦 ZA Tanzania🇺🇸 US

Who might be able to join this trial: - People who have symptoms that could suggest bowel cancer, such as rectal bleeding lasting a week or more - People who are attending a routine bowel cancer screening colonoscopy - People who have received a confirmed diagnosis of bowel cancer through a colonoscopy or surgical samp...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07669220 · Sixth Affiliated Hospital, Sun Yat-sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2028
🇨🇳 CN

Who might be able to join this trial: - People who have voluntarily signed and dated a consent form before any study-related procedures begin. - People aged between 18 and 75 years. - People who have been diagnosed with a specific type of rectal cancer (called pMMR/MSS rectal adenocarcinoma) confirmed through laborator...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07669454 · Natureceuticals Sdn Bhd Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 October 2026
🇮🇳 IN

**Who might be able to join this trial:** - People aged 18 to 65 years old who are willing to give their consent to take part in the study. - People who have been diagnosed with colorectal cancer that has spread to other parts of the body (metastatic), and who are planned to receive standard chemotherapy for at least...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07669519 · Natureceuticals Sdn Bhd Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 March 2027
🇮🇳 IN

**Who might be able to join this trial:** - Adults aged 18 to 65 years who are willing to give their consent to take part in the study. - People who have been diagnosed with colon cancer and are planned to receive standard chemotherapy for at least 3 cycles. - People whose colon cancer diagnosis has been confirmed foll...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07687875 · Henry Smith Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 December 2028
🇩🇰 DK

Who might be able to join this trial: - People who have been diagnosed with primary rectal cancer that has not spread to other parts of the body, confirmed through a tissue sample, and falls within a specific stage range (confirm with trial site for exact staging details) - People whose rectal cancer has been tested an...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07692152 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 March 2029
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with anal squamous cell carcinoma, or certain rectal squamous cell carcinomas that meet specific medical criteria (confirm with trial site for details on rectal cases) - People whose cancer has been staged at a certain level using imaging scans — sp...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07696793 · Fundacion Clinic per a la Recerca Biomédica Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 May 2028
🇪🇸 ES

**Who might be able to join this trial:** - People aged 50 to 69 years old - People who have taken part in an early detection program for colorectal (bowel) cancer - People who had a positive result on a stool blood test (a test that checks for hidden blood in the stool, at a level of 20 μg Hb/g feces or above) - Peopl...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07703709 · Chou-Chen Chen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇹🇼 TW

Who might be able to join this trial: - People aged 20 years or older - People who have been diagnosed with colorectal cancer - People who started cancer treatment at some point between January 1, 2025 and December 31, 2027 Who may not be able to join: - No exclusion criteria have been listed for this trial (confirm w...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07705139 · Zhongnan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 May 2026
🇨🇳 CN

**Who might be able to join this trial:** - People between 18 and 80 years of age - People who have been diagnosed with colorectal adenocarcinoma (a specific type of bowel cancer), confirmed by laboratory testing of tissue, according to the WHO 2022 classification - People who have previously received treatments such a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07705880 · University Hospital, Ghent Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2030
🇧🇪 BE

**Who might be able to join this trial:** *For endoscopists (doctors who perform colonoscopies):* - Doctors who perform colonoscopies, at any experience level or grade, may be eligible to participate - The endoscopist must not have previously used the clinical decision support tool being studied in this trial *For pa...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07718490 · The First Affiliated Hospital with Nanjing Medical University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who are able and willing to give written consent to take part in the study voluntarily. - People aged between 18 and 75 years old (inclusive), of any gender. - People whose colorectal cancer has spread to other parts of the body (metastatic), confirmed by a laboratory...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Advocacy and support in Australia

Organisations that can offer information, support, or connection for Colorectal Cancer. Where more than one is listed, they serve different needs or regions, so choose whichever fits your situation.

Bowel Cancer Australia is the national advocacy and support body for bowel (colorectal) cancer.

This is a starting point, not medical advice or an endorsement. Contact details change; search the organisation name to find its current website.